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SUMMARY

CELF6 is a CELF-RNA-binding protein, and thus part of a protein family with roles in human disease; however,
its mRNA targets in the brain are largely unknown. Using cross-linking immunoprecipitation and sequencing
(CLIP-seq), we define its CNS targets, which are enriched for 30 UTRs in synaptic protein-coding genes. Using
a massively parallel reporter assay framework, we test the consequence of CELF6 expression on target sequences, with and without mutating putative binding motifs. Where CELF6 exerts an effect on sequences, it is
largely to decrease RNA abundance, which is reversed by mutating UGU-rich motifs. This is also the case for
CELF3–5, with a protein-dependent effect on magnitude. Finally, we demonstrate that targets are derepressed in CELF6-mutant mice, and at least two key CNS proteins, FOS and FGF13, show altered protein
expression levels and localization. Our works find, in addition to previously identified roles in splicing, that
CELF6 is associated with repression of its CNS targets via the 30 UTR in vivo.

INTRODUCTION
RNA-binding proteins (RBPs) regulate the life cycle of messenger
RNAs (mRNA), from transcription, splicing, and nuclear export to
localization, maintenance, translation, and degradation (Vindry
et al., 2014; Xiong et al., 2015). The CUGBP and ELAV-like factor
(CELF) family of RBP has six members (CELF1–6), which can be
divided into two groups based on sequence homology: CELF1–
2, which are expressed ubiquitously, and CELF3–6, which show
enrichment in the CNS (Dasgupta and Ladd, 2012). The most
studied, CELF1, was first characterized in relation to myotonic
muscular dystrophy pathogenesis (Lee and Cooper, 2009). It
binds CUG- and (U)GU-rich motifs (Timchenko et al., 1996;
Wang et al., 2015) and has been shown to promote exon skipping
(Wang et al., 2015) as well as mRNA degradation via recruitment
of deadenylases (Moraes et al., 2006). CELF3–6, however, have
not been as well characterized.
We identified CELF6 to be both enriched in serotonin-producing neurons and disrupted in an individual with autism (Dougherty et al., 2013). CELF6 showed expression in the hypothalamus
and in several monoaminergic cell populations commonly targeted in psychiatry (Maloney et al., 2016). Likely as a consequence of its role in those cells, it is also associated with conditioned behaviors: Celf6-knockout (KO) mouse pups show altered
ultrasonic vocalization, while adults exhibit deficits in fear conditioning and loss of conditioned place preference to cocaine
(Dougherty et al., 2013; Maloney et al., 2019). Although capable

of regulating splicing in vitro (Ladd et al., 2004), CELF6 has
recently been shown to interact with the 30 untranslated region
(UTR) as well, allowing it to stabilize p21 mRNA in colorectal cancer cells (Liu et al., 2019). Its targets and function in the CNS,
however, are not well described. Here, we sought to explore
the molecular role of CELF6 in the brain to better understand
how its disruption may alter behavior.
To define the function of CELF6 in vivo, we performed crosslinking immunoprecipitation and sequencing (CLIP-seq) in the
brain and found CELF6 to be overwhelmingly associated with
30 UTRs of target mRNAs, many coding for proteins involved in
synaptic transmission. UTRs showed enrichment for UGU-containing motifs, consistent with prior in vitro findings (Ray et al.,
2013), as well as other motifs. We cloned UTR elements under
CLIP-seq peaks into the 30 UTR of a reporter construct and
measured reporter library expression and abundance on translating ribosomes while modifying CELF6 expression and
sequence integrity. We found CELF6-associated UTR sequences were repressive in general, CELF6 could function to
enhance this reduction to mRNA levels, and this effect could
be abrogated by motif mutation. We also observed this effect
across CELF3–6. In the Celf6-KO mouse brain, we find CELF6
targets to be generally derepressed, validating our findings
in vivo. Taken together, we show that CELF6 is largely associated with reductions to transcript abundance of its neuronal targets and thus may have an important role regulating cellular
functions in the brain.
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Figure 1. CELF6 Primarily Associates with 30 UTRs of Target mRNAs In Vivo
(A) CELF6 CLIP, lanes: no crosslink (no XL), wild-type (WT) control, and three concentrations of RNase If. Top: RNA 32P autoradiogram. Bottom: anti-GFP
immunoblot. Scissors mark region (80–150 kDa) above CELF6-HA/YFP (78 kDa) isolated for sequencing. Immunoblot detects two bands, corresponding to sizes
of known isoforms of CELF6.
(B) Log2 counts-per-million (CPM) RNA in four CELF6-HA/YFP+ replicates and three WT replicates differentially abundant regions. Heatmaps show enrichment in
HA/YFP+ immunoprecipitate (IP) samples relative to input and WT controls. CPM is normalized to mean YFP input by row.
(C) Summary of differential enrichment analysis of genes showing nominally significant (p < 0.05), and Benjamini-Hochberg (FDR < 0.1) enrichment in HA/YFP+ IP
samples relative to both HA/YFP+ input and WT IP controls. No peaks were found in intergenic regions.
(D) Average phastCons score for ±100 bp around CLIP peaks in targets compared with control genes not exhibiting enrichment in CLIP (p < 2.2 3 1016, twotailed t test).
(E) Overlap of CELF6 and CELF4 targets identified in Wagnon et al. (2012).
(F) DAVID gene ontology analysis of CELF6 CLIP targets (241 unique genes).

RESULTS
CELF6 Associates with Conserved Elements in 30 UTRs
of Target mRNAs In Vivo
We first sought to use CLIP to identify CELF6 targets in vivo. Unfortunately, available antibodies against CELF6 protein do not
function well for immunoprecipitation against endogenous
protein (data not shown). We previously developed a BAC
transgenic mouse expressing epitope-tagged CELF6-YFP/HA
(78 kDa), which exhibits endogenous patterns of anatomical
and subcellular (cytoplasmic and nuclear) expression, with only
slight overexpression compared with native CELF6 (Maloney
et al., 2016). Because we have previously validated antibodies
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for GFP (and related YFP) pull-down (Doyle et al., 2008), we designed our CLIP studies using that line.
To establish the in vivo RNA-binding properties of CELF6, we
first performed CLIP with anti-EGFP antibodies on CELF6-YFP/
hemagglutinin (HA) mice followed by radiolabeling of nucleic
acid (Figure 1A). Controls included an immunoprecipitate (IP)
from uncrosslinked samples and IP from wild-type (WT) tissue.
As expected, there was a lack of detectable RNA in IP from
WT tissue and uncrosslinked YFP+ tissue. To capture the targets
of CELF6 in vivo, we purified a region of 60–200 nucleotides in
size (80–150 kDa) from lysates of CELF6-YFP/HA+ brains. Similar
to the Vidaki et al. (2017) study of Mena, we found that the stringent IP conditions of standard CLIP protocols were incompatible
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with our anti-GFP IP (not shown). Thus, to enable statistical
background estimation, we also collected samples from sizeselected input RNA (controlling for differences in RNA abundance), as well as pull-down from WT littermate brains (to control
for non-specific binding). We defined high-confidence targets as
those showing statistical enrichment in CLIP samples compared
with both controls and we defined lower-confidence targets as
showing enrichment against only one control.
We prepared sequencing libraries from those samples using
an adaptation of the eCLIP workflow (Van Nostrand et al.,
2017) (Methods S1). All samples were sequenced to a similar
depth, and, on average, 94% of reads mapped to genic regions
(Table S1). Next, to define specific sites of CELF6 binding, we
called peaks genome-wide using Piranha (Uren et al., 2012)
and performed differential enrichment analysis using edgeR
comparing CLIP to controls for read counts under peaks (Robinson et al., 2010). In the event that genome-wide background
count estimation in Piranha would limit discovery, we also
summed reads mapping to smaller subgenic features: 50 UTR,
coding sequence (CDS), intron, or 30 UTR and performed differential enrichment analysis restricted to those regions. In total, we
identified significant enrichment across 241 genes combined
across analysis methods (Table S2).
CELF proteins have been shown to function both in splicing
and post-transcriptional regulation. To understand how CELF6
may function in the brain, we examined the distribution of CLIP
reads across genes. We hypothesized that splicing-related functions would correspond to increased density in internal coding
exons and introns, whereas post-transcriptional regulation
would be reflected as increased density in UTRs. Figure 1B
shows a heatmap of CLIP targets across all samples relative to
controls. Most enriched regions are in 30 UTRs (Figure 1C;
>80%). Additionally, UTRs showing CELF6 binding were more
conserved than expected by chance (Figure 1D). We also
compared our CLIP hits to the top-ranking targets of the related
protein CELF4 (Wagnon et al., 2012). Figure 1E shows this overlap—with 70/241 CELF6 target genes in common with CELF4
target genes (also noted in Table S2). The Wagnon et al. (2012)
study was performed on different brain regions, cell types, and
at different ages, and thus, this overlap is notable. CELF6 targets
were also disproportionately involved in synaptic transmission
(Figure 1F). Taken together, these data suggest CELF6 may
regulate neuronal function by binding UTRs of synaptic gene
transcripts, altering their stability or translation.
CELF6-Bound 30 UTRs Are Enriched for U-, UGU-, and
CU-Containing Motifs
Previous study in vitro has identified CELFs as preferring UGUrich sequences (RNACompete; Ray et al., 2013) and manual inspection under CELF6 clip peaks found matches to those motifs
(Figure 2A). To scan CLIP targets systematically and potentially
identify other preferred sequences in the brain, we used
MEME-SUITE to search for motif enrichment. We analyzed 50
nucleotide segments centered under 544 peaks. Those included
25 30 UTR peaks (25 unique genes) identified using Piranha
genome wide. However, we performed a second pass of peak
calling in those UTRs identified via summation across the UTR
(as described in the preceding section). Doing so enabled us to
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discover an additional 519 peaks in 191 UTRs, including new
peaks in 10 genes identified in the initial genome-wide pass.
We suspect the additional discovery is due to incorrect background estimation when using read counts across an entire
gene or genome wide versus more local background-count estimation. UTRs varied between 1 and 9 peaks with a median of 2,
with 75% of the UTRs containing 1–3 peaks. We compared those
sequences to 544 control sequences sampled randomly from
UTRs of brain-expressed genes showing no CLIP enrichment.
We found 29 enriched motifs at a false discovery rate (FDR) <
0.05, including the RNACompete binding motifs for CELFs. We
also found U-rich motifs of the TIA/CPEB families to be enriched,
among others. Because RBPs can exhibit degenerate preferences (Auweter et al., 2006; Harvey et al., 2018), for a more holistic summary, we clustered enriched motifs by the Euclidean
distance between their position probability matrices (PPMs)
in the CISBP-RNA database. As expected, enriched motifs
clustered partially by RBP family (Figure 2B), and motifs within
a cluster were highly similar. After clustering, we scanned our
sequences again to determine which showed matches to the
cluster-average PPMs, as ‘‘meta-motifs.’’ We found that 519/
544 sequences showed significant matches to at least one cluster (Tables S3 and S4).
A few of these clusters were highly recurrent (Figure 2C;
Tables S3 and S4); 140/206 unique genes’ 30 UTRs (68%)
showed at least one match to the ‘‘CELF’’-cluster ([U/A]
GUGU[G/U][UGA]), and 131/206 UTRs (63.6%) showed at
least one match to the PCBP3 motif, which forms its own cluster with a central UUU[C/U]CC sequence. PCBP3 binds both
double- and single-stranded nucleic acids, known primarily
as a transcription factor (Choi et al., 2009), though a related
protein (PCBP4) has also been shown to regulate mRNA stability (Scoumanne et al., 2011). 120/206 (58.2%) genes
showed at least one match to the ‘‘U-rich’’ cluster, whose
members all possess a central stretch of 4–5 Us. Proteins in
this cluster include TIA1, involved in stress granule localization
(Gilks et al., 2004); CPEBs, involved in polyadenylation (Villalba et al., 2011); and HNRNPC, involved in both mRNA stability and localization (Nakielny and Dreyfuss, 1996; Shetty,
2005). Moreover, 61/206 genes (29.6%) had R1 match to
both the CELF cluster and the U-rich cluster, and 65/206
genes (31.5%) had R1 match to both the CELF and PCBP3
clusters. Thus, CELF6 binding appears to be associated with
combinations of known motifs for both CELFs and other
RBPs, and not just UGU-rich sequences.
We also tested whether CELF6 peaks had location biases within
UTRs that might suggest function, such as an enrichment near a
polyadenylation signal (PAS). We found a small increase in the
number of predicted PASs per transcript compared with lengthmatched UTRs from control genes (p = 0.00023; Figure S1C),
as well as decreased distance between CLIP peaks and a PAS
(p = 5.3E6; Figure S1D). In the case of UTRs with only one
predicted PAS, this was true only for the PAS [ATTAAA], but not
[AATAAA] (p = 0. 00154; Figure S1E). Although these findings
suggest that CELF6’s proximity may influence choice of PAS, an
examination of alternative polyadenylation in vivo in Celf6-KO
mice did not show CELF6 to alter the probability of alternative 30
UTR usage (not shown, available at GEO: GSE160293).
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Figure 2. CELF6-Associated 30 UTRs Are Enriched for U-, UG-, and CU-Containing Motifs
(A) Example 50-nt regions under CLIP peaks.
(B) Clustering of enriched motifs identified with MEME-SUITE. Color coding shows cluster membership.
(C) Motif logos for the clusters found under the CLIP peak. Logos represent the average of position probability matrices (PPMs) for each motif cluster. Side panels
show individual PPMs making up each cluster’s membership.

Massively Parallel Reporter Assay Defines the Function
of CELF6-Bound Motifs
Motif analysis indicates that sequence specificity mediates interactions between CELF6 and RNA in vivo, so we next sought to
understand the consequence of that association, such as on

4 Cell Reports 33, 108531, December 22, 2020

translation or transcript stability. We used a massively parallel reporter assay framework for post-transcriptional regulatory
element sequencing (PTRE-seq) to evaluate a large number
of target UTR sequences at once (Cottrell et al., 2018). For
PTRE-seq, we sub-cloned 410 independent, CLIP-defined
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UTR elements, each 120 bp long and centered under CLIP
peaks, into the 30 UTR of a tdTomato expression plasmid (Figure 3A). That library included 254 high-confidence targets
showing enrichment against both CLIP controls (input and WT/
non-specific pull-down). We also included cloneable elements
from 156 additional elements under peaks that only met the input
comparison criterion (lower stringency, highlighted in green dots
going forward). As these performed similarly, we included both
sets in subsequent figures. For reproducibility, each UTR
element was included in the library six times, with unique 9-bp
barcodes. As a comparison group, we also included 410 elements with all significant motif matches mutated. Sequences
and their mutations are shown in Table S5.
We assayed the effect of each element on both transcript
abundance and final translation levels, as assessed by ribosome
occupancy of those reporters. We used transient cotransfection
of the library with an EGFP/RPL10A construct that tags ribosomes with GFP enabling translating ribosome affinity purification (TRAP). This method allows assessment of RNA abundance
on ribosomes by anti-GFP pull-down and has previously been
shown to be sensitive to UTR elements that regulate translation
(Heiman et al., 2008). To assess transcript abundance, we also
collected total RNA from the same cells. We opted for an
in vitro culture system with largely undetectable levels of
CELF6 expression: SH-SY5Y neuroblastoma cells (Figure 3B),
so that we could control CELF6 expression exogenously,
confirmed by RT-PCR (Figure S2).
We assessed expression of PTRE-seq library sequences by
counting barcodes in sequencing libraries prepared from transient transfection replicates. Pearson correlation in barcode
counts between replicates was >0.9, indicating good reproducibility. To account for any differences in starting abundance within the library itself, log2 counts per million (CPM)
in RNA barcodes were further normalized to log2 CPM from
sequencing the starting DNA plasmid pool (normalized count
data hereafter termed ‘‘log2 expression’’). After removing
barcodes that were absent or poorly measured across all samples, the final analyzed library contained 379 UTR element
pairs (reference and mutant, 229 high-confidence targets
and 150 lower-stringency targets); all of which were represented by three to six barcodes per element, across 153 total
genes (104 high-confidence genes and 49 lower-stringency
genes).
To determine the relationship between CELF6 expression
and element sequence, we analyzed log2 TRAP levels using
a 2 3 2 factorial design linear mixed-effects model, fitting
fixed effects of the element sequence (‘‘reference’’ or
‘‘mutant’’) and the CELF6 expression condition (control [CTL]
or CELF6 expression) and the interaction of the condition X
sequence, with a random intercept term for replicate sample,
treating an element’s barcodes within a sample as a repeated
measure. Individual models were fitted for each UTR element
pair. A summary of effects across all library elements and estimates of R2 are shown in Table S6. At nominal p < 0.05, 293/
379 (77.3%) of elements showed some significant effect (main
effects of either sequence or CELF6 expression or a
sequence-X CELF6-expression interaction, 283/379 [74.7%]
at FDR < 0.1).
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CELF6-Associated Motif Sequences Decrease RNA
Abundance and Corresponding Ribosome Occupancy
We first examined the role of the element sequence itself on ribosome occupancy by comparing the UTR elements with and
without motif mutations in the TRAP data in the empty-vector
condition. Among the 77.3% of elements showing any significant
effect, 88% (258/293 elements) showed a main effect of
sequence, regardless of CELF6 expression. Looking at the distribution of log2-fold changes in expression between reference and
mutant sequences under CTL transfection conditions, 220/258
(85.3%) of them were repressive when compared with their
mutated counterparts (median log2-fold change: 0.47; 1.39fold decrease). CELF6-bound elements decreased ribosome occupancy, even in the absence of CELF6 expression.
There are two primary mechanisms by which a sequence can
alter ribosome occupancy—altering translation efficiency (TE),
usually reflecting the loading of mRNAs onto ribosomes, or
altering mRNA stability (Garneau et al., 2007; Hinnebusch
et al., 2016; Ivshina et al., 2014; Piqué et al., 2008). To assess
TE, log2 expression for each barcode in the TRAP samples
was normalized to input RNA to account for their overall abundance (log2 TE). We then fit our model independently for both
input RNA expression and TE. A summary of those effects is
shown in Tables S7 and S8.
To assess relative influence of either mechanism, we first
looked at input RNA expression; 285/379 elements (75.2%)
showed any significant effect (282/379, 74.4% at FDR < 0.1).
Similar to what was found in the analysis of TRAP RNA levels,
89.8% of them (256/285) showed a main effect of sequence mutation, regardless of CELF6 expression. Similar to ribosome occupancy, 86.3% had fold changes less than 0, indicating that
reference sequences are repressive when compared with their
mutated counterparts (Figure 3C) (median log2-fold change:
0.47; 1.39-fold decrease). We did not observe a similar trend
in TE. Only 34/379 sequences (8.97%) showed any nominally
significant effect on TE, and 0 showed any significant effect at
FDR < 0.1; 15/34 showed a significant effect of sequence; however, six showed negative log2-fold changes, and nine showed
positive fold changes. This indicates that alteration of transcript
abundance is the primary mechanism leading to decreased ribosomal occupancy, rather than changes in TE.
Significant changes to expression could be incurred because
of large numbers of mutated bases. Thus, we looked at changes
between reference and mutant for elements with smaller
amounts of mutation (Hamming distance [HD] of %8, the
approximate size of a motif, or %16 nucleotides; maximum
HD = 25 for any element). Expression of reference sequences
was generally lower than mutant sequences for these subsets,
with 72.9% at <0 and 84.8% at <0 for HD %8 and HD %16,
respectively (Figure 3C). Thus, even a modest amount of mutation is capable of elevating the expression levels of most
elements.
CELF6 Decreases RNA Abundance in a SequenceDependent Manner
We next assessed interactions between CELF6 expression and
sequence, focusing on RNA expression; 16 elements (15 unique
genes) showed a nominally significant interaction (p < 0.05)
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Figure 3. CELF6-CLIP-Enriched Motif Sequences Represent a Set of Repressive Elements
(A) PTRE-seq reporter (pmrPTRE_AAV).
(B) Fragments per kilobase of transcript per million reads (FPKM) levels are shown for several RNA-binding proteins in SH-SY5Y cells (n = 8). Lines represent
median FPKM.
(C) Reporter RNA log2-fold changes in expression (reference versus mutant) in CTL transfections, for all element pairs, as well as Hamming distance (HD) % 8 or % 16.
(D) Reporter RNA log2-fold changes between reference and mutant in CTL and CELF6 expression conditions, from elements showing significant condition X
sequence interactions.
(E) Reporter RNA log2-fold changes in translation efficiency (TE) between reference and mutant in CTL and CELF6 conditions, for elements in (D). Data points in
(C)–(E) are log2-fold changes (reference versus mutant) per condition, averaged by replicate over barcodes and then over replicates. Lines represent medians.
Comparisons between conditions or sequence mutation were assessed by Mann-Whitney U tests.
(F) Log2 expression across five example reporter library elements in CTL, CELF6, reference, and mutant conditions.
(G) Log2 TE across example reporters in (F). Data points in (F) and (G) are averaged across barcodes for each biological replicate.
Lines in (F) and (G) represent average ± 95% confidence intervals, normalized to CTL/reference condition. Post hoc pairwise comparisons in (F) and (G) computed
using the multcomp package in R. n.s., p > 0.1; yp < 0.1, *p < 0.05, **p < 0.001, ***p < 0.0001, ****p < 1E5. Green points represent library elements selected from
less-stringent CELF6 target criteria (enrichment over input alone).
Scale bar in (A) represents 0.1 mm as indicated.
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between CELF6 expression and sequence. Figure 3D plots the
average log2-fold change between reference and mutant
sequence for both the CTL and CELF6 conditions across each
subsetted level of sequence mutation. The fold changes between reference and mutant sequences were more negative
(median: 1.4-fold) under CELF6 expression. That is driven by
repression of the reference sequence, rather than an elevation
of the mutant sequence by CELF6 (median log2-fold change
CELF6-CTL reference = 0.37, CELF6-CTL mutant 0.05;
p = 9E4, Mann-Whitney U test). This indicates the CELF6
affects those elements by further decreasing mRNA levels, and
that effect is sequence dependent.
As mentioned earlier, few effects were observed on TE by
comparison. Only 8/34 elements with any effect on TE showed
interactions with CELF6 expression at p <0.05, with 0 showing
interactions at FDR <0.1 (Figure 3E). Additionally, we did not
detect a consistent direction of CELF6 effect on TE. Looking at
changes to reference sequence TE when CELF6 is overexpressed, only two elements showed a trend to difference
compared with CTL, one showing a decrease (Lin7c, log2-fold
change: 0.45; p = 0.05) and one showing an increase (Enc1,
log2-fold change: +0.71; p = 0.052). Other elements had different
sources of interaction, e.g., a difference between CELF6 and
CTL only in mutated elements (e.g., Prkacb, log2-fold change
in mutated sequence only: +0.29; p = 0.002). By contrast, looking
at input RNA expression, 14/16 elements with nominally significant interactions showed log2-fold changes in the reference between CELF6 and CTL, changes that were negative. Examples of
element expression are shown in Figures 3F, and Figure 3G
shows TE. These findings indicate that, for elements showing interactions between CELF6 and element sequence, there is a
repression of the reference sequence via a decrease in RNA
abundance with CELF6 expression, and that effect is abolished
after mutation of the conserved motifs. Therefore, we conclude
that, overall, when CELF6 exerts a measurable effect in our system, that effect is to decrease RNA abundance. Where impact on
TE occurs, it is not generalizable in the direction of the effect.
To further validate these findings and confirm an effect on final
protein levels, we overexpressed five individual reporters, with
and without mutation, along with EGFP-tagged CELF6 or
EGFP alone, then measured reporter expression by tdTomato
fluorescence (Figure 4). For 4/5 cases, repression upon CELF6
expression was the same direction and magnitude to that
observed by PTRE-seq. For 3/4, the repression observed by
CELF6 was significantly reversed by motif mutation. This shows
that this finding ultimately affects target protein levels.
CELF3–5 Also Decrease RNA Abundance
CELF3, CELF4, and CELF6 binding preferences determined by
RNAcompete are highly similar (Figure 2), and as a group,
CELF3–6 are more similar in amino acid identity than CELF1 or
CELF2 are (Dasgupta and Ladd, 2012). Therefore, we hypothesized that the repression we observed with CELF6 would also
be true of CELF3–5. We transiently transfected our PTRE-seq library along with His/Xpress-tagged human CELF3, CELF4, or
CELF5 used previously to study these proteins (Figure S2)
(Ladd et al., 2001, 2004). We then performed the analysis of
mRNA abundance described in the preceding section, refitting
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the linear mixed models to include data from these new expression conditions (Figure 5).
There were 63/379 (p < 0.05; 42/379 with FDR < 0.1) elements
representing 63/153 genes showing a nominally significant
sequence by CELF-expression interactions in the total reporter
RNA. Looking at the log2-fold change in the reference versus
the mutant sequence, CELF3 and CELF4 showed the largest differences (Figure 5A). The median log2-fold change in the reference versus the mutant sequence in the CELF3 expression condition was 1.22, with comparable change under CELF4
expression (1.06) (CTL median log2-fold change: 0.36; CTL
versus CELF3 p = 9.5E13; CTL versus CELF4 p = 1.2E11;
and CELF3 versus CELF4 p = 0.31; Mann-Whitney U tests).
CELF6 and CELF5 also showed comparable fold changes, and
those were intermediate between the CTL condition and
CELF3 or CELF4 conditions (CELF5: 0.58, CELF6: 0.57;
CELF5 versus CTL, p = 0.0025; CELF6 versus CTL, p =
0.0016; CELF5 versus CELF6, p = 0.57). These rankings were
consistent at both low (HD % 8) and higher (HD % 16) levels of
sequence mutation (Figures 5B and 5C). Thus, expression of
any of these CELFs was able to reduce abundance of reference
reporters, an effect that could be abolished by mutation. Furthermore, CELF3 and CELF4 were associated with the strongest
effects, whereas CELF5 and CELF6 showed more moderate
effects. Thus, within these CELF proteins, CELFs 5/6 and CELFs
3/4 appear to form distinct subgroups with respect to their
effects on mRNA abundance.
When looking at TE, there were fewer significant effects. Nine
elements showed significant interactions of condition by element
sequence (p < 0.05, 0/379 at FDR < 0.1). However, when plotted
in terms of their fold change between reference and mutant
sequence, we were again unable to generalize a direction of effect on TE across elements. Median log2-fold changes in TE
were near 0, with no significant differences across conditions
(Figures 5D–5F). Thus, CELF expression decreased overall ribosome occupancy of reference elements, but largely by disrupting
reporter transcript abundance. Total reporter expression for key
examples are shown in Figure 5G with their respective TE shown
in Figure 5H. Among significant CELF by sequence interactions,
6/63 showed significant reductions between a CELF condition
and CTL in the mutant sequence (Slc39a6, Olfm1, Slc25a1,
Pcdh17, Zbtb5, and Socs5). However, even though these mutant
sequences appeared to respond to the CELF condition, their
respective reference sequences were still more negative (Table
S7). Thus, we find, in general, the effect of CELF by sequence
interaction to be a CELF-associated decrease in reporter levels
for elements with intact motifs.
Because expression of various CELFs may overlap in the
brain, we next tested combinatorial effects of co-expressing
CELF proteins. We transfected CELF6 construct with one of
CELF3–5 in equimolar proportions. Among elements showing
significant sequence-by-condition interactions, expression of
CELF3 and CELF6 together resulted in repression similar to
CELF3 by itself (median CELF3/CELF6 log2-fold change reference versus mutant: 1.23, CELF3 alone: 1.22; p = 0.37).
This was also true of CELF4 (median CELF4/CELF6 log2-fold
change: 1.13, CELF4 alone: 1.06; p = 0.34). Thus, the effect
of CELF4 and CELF3 appears to be dominant, or at least
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Figure 4. Individual mtdTomato UTR Element Constructs Replicate Interactions of CELF6 Expression and Sequence
Individual UTR elements were cloned as in Figure 3A and transfected along with either EGFP or EGFP-CELF6
(A) Example of live-cell epifluorescent images from a transfection experiment showing EGFP or EGFP-CELF6 expression (top panels) and either tdTomato:EPM2AIP1 or tdTomato:EPM2AIP1(mutant) (bottom panels).
(B–F) tdTomato log2 fluorescence, with lines representing means normalized to EGFP/reference sequence.
Significance was assessed by two-way ANOVA, with post hoc pairwise comparisons using the multcomp package in R. n.s., p > 0.1; yp < 0.1, *p < 0.05, **p <
0.001. Green points represent library elements selected from less-stringent CELF6 target criteria (enrichment over HA/YFP input alone). Scale bar in (A) represents 0.1 mm as indicated.

maximal, in these co-transfections, not because of differences in
the level of each CELF’s expression (Figure S2). When CELF5
and CELF6 were expressed together, the median log2-fold
change of reference versus mutant sequence was more negative
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comparison did not reach significance compared with CELF5
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Figure 5. CELF3–5 Show Redundancy in Ability to Enhance Repression of CELF6-CLIP-Enriched UTR Elements
(A–C) Log2-fold change across CELF conditions considering all reporter elements, or reporter elements with HD % 8 or % 16, for any element with significant
condition X sequence interactions.
(D–F) Log2-fold change in TE for conditions, as in (A)–(C). Data points in (A)–(F) were averaged for redundant barcodes, then, across replicates, with lines representing medians. Statistical comparisons in (A)–(F) were assessed by Mann-Whitney U tests.
(G) Log2 expression across five example reporter library elements across CELF, reference, and mutant conditions.
(H) Log2 TE across example reporters in (G). Data points in (G) and (H) are averaged across barcodes, with each dot representing a replicate.
As in Figure 3, horizontal lines in (G) and (H) represent average expression or TE ± 95% confidence intervals, normalized to the CTL/reference. Post hoc pairwise
comparisons in (G) and (H) computed with multcomp in R. n.s., p > 0.1; yp < 0.1, *p < 0.05, **p < 0.001, ***p < 0.0001, ****p < 1E5. Green points represent library
elements selected from less-stringent CELF6 target criteria (enrichment over HA/YFP input alone).
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Figure 6. CELF6 Targets Identified by CLIP Show Increased Expression in Celf6-Knockout Brains
(A) Volcano plot showing gene-expression changes in Celf6 KO versus WT mouse brains.
(B) Celf6 mRNA is decreased in KO brains as expected (p < 1 3 106).
(C) CLIP targets (orange) are derepressed in KO brains compared with other genes (p < 1.1 3 109, Welch’s t test).
(D) Example of anti-FGF13 staining in LC.
(E) IF Analysis, left: FGF13 staining (red) with overlay showing quantification. Example images were selected to be near the mean of the data. Right: tyrosine
hydroxylase (TH) and DAPI staining.

(legend continued on next page)
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alone (CELF5 alone: 0.58; p = 0.19). Nevertheless, that may
indicate that CELF5 and CELF6 can act additively. Overall, our
reporter assays show that CELF proteins suppress mRNA abundance of targets containing specific sequence motifs.
CELF6 Regulates Transcript Abundance in the Brain
We next determined whether CELF6 affects target transcript
abundance in vivo when CELF6 is absent. We examined targets
by microarray analysis, comparing eight WT and eight Celf6-KO
brains. Microarray probes measuring Celf6 are reduced, confirming loss of transcript, in the KO mouse (Figure 6B). Effects
of CELF6 loss on total brain RNA abundance are modest:
whereas several hundred genes show a nominally significant
change in RNA abundance (Figure 6A), the median log2-fold
change is 0.24, and only the Celf6 probes survive multiple testing
corrections. However, examining the distribution of fold changes
in CLIP targets compared with randomly selected probes,
showed increased abundance in KO brains (p < 1.11E09,
Welch’s t test) (Figure 6C). This is consistent with a role for
CELF6 in decreasing target stability in vivo. Given that CELF6
expression is restricted regionally (Maloney et al., 2016) and
brain CELFs may have overlapping activity, modest changes
are unsurprising. This experiment also combines direct effects
on CELF6 targets and indirect effects on gene expression
because of development in the KO background. However,
despite those limitations, we see nominally significant (p <
0.05) regulation of several high-confidence CELF6 CLIP targets,
including important neuronal signaling genes, such as Reln and
Fgf13, as well as genes meeting lower-stringency criteria, such
as Fos and Mecp2 (Figure S3); 20/21 measurement CELF6 targets change in the expected direction, showing increased
mRNA levels in the KO, a result highly unlikely to be due to
chance (p < 0.0005, c2 test). This is driven by the 30 UTR CLIP targets, (p < 2.2E08; Figure 6C) because we did not detect
changes in target genes identified via 50 UTR or intronic binding.
A few targets identified via binding in the CDS show a similar
magnitude of increase in the KO; however, that did not reach statistical significance. Thus, overall, our analysis indicates CELF6
deletion is generally associated with an increase in the RNA
abundance of its targets, in vivo, as it does in reporter assays
in vitro.
A systems analysis of the consequences of CELF6 loss is also
intriguing (Figure S3C). Gene Ontology of the 200 most-upregulated genes in the KO brains (p < 0.05), regardless of CLIP status,
reveals significant enrichment for terms for transcription regulators (transcription factor complex, p < 0.8E3 with BenjaminiHochberg [B-H] correction) and other components of the nucleus, as well as synaptic genes (growth cone, p < 3.47E4,
and dendritic spine, 4.02E3). Downregulated genes showed
no such consistent enrichment, with only a single category
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showing downregulation (flagellum, p < 9.62E3). Thus, loss of
CELF6 appears to dysregulate both nuclear transcription and
synaptic genes in vivo.
CELF6 Regulates FOS and FGF13 Protein Abundance
and Localization in the Locus Coeruleus
Finally, we tested the effect of Celf6 KO on target protein levels
and localization in vivo. CELF6 is expressed sparsely in the brain,
and immunoblots would be uninformative. We, therefore, began
with CLIP targets in which antibodies had been previously validated for immunofluorescence in the brain. We focused on fibroblast growth factor 13 (FGF13), a non-canonical FGF previously
shown to bind intracellularly to voltage-gated sodium channels
and regulate their subcellular spread (Pablo et al., 2016). Additionally, we looked at FOS (a lower-stringency target), an immediate
early gene stimulated by neuronal activity and involved in downstream synaptic changes required for phenomena such as longterm potentiation (Abraham et al., 1991). We assayed expression
in the locus coeruleus (LC), a stress-responsive neuromodulatory
nucleus, identifiable by location and tyrosine hydroxylase (TH)
staining, with robust CELF6 expression in WT mice (Maloney
et al., 2016). To enable detection of FOS, animals were first subjected to restraint stress to activate the LC. We confirmed the antibodies produced a detectable signal in the LC under those conditions (Figures 6D and 6H). Because localization is important to
the function of both proteins, the FGF13 or FOS signal was quantified for both fluorescence intensity and subcellular compartment
(cytoplasmic or nuclear), as determined by DAPI or TH staining,
respectively (Figures 6E–G and 6I–6K).
In the case of FGF13, we observed a significant increase
(~20%) in the cytoplasmic KO mean expression (Figure 6E;
log2 (intensity/area) cytoplasm = 4.53, nucleus = 4.25; p <
0.001; log2-fold change, cytoplasm  nucleus = 0.28), whereas
we did not observe a significant change between WT cellular
compartments (log2-fold change = 0.013). Additionally, we
observed a significant increase (~10%) in KO cytoplasmic
FGF13 spread (Figure 6F) quantified as the percentage of cytoplasmic area containing a signal above background (KO cytoplasmic mean = 74.6%, KO nuclear mean = 64.2%; p <
0.0001). In the WT, we did not detect a significant difference,
although we observed an opposing trend with ~3% change in
the area with a signal (WT cytoplasm = 66.9%, WT nucleus =
64.2%; p = 0.066).
In the case of FOS, we observed a small increase in signal
(~10%) in the cytoplasm compared with the nucleus (Figure 6H;
KO cytoplasmic log2 intensity/area = 4.23, KO nucleus = 4.1; p <
0.0001; log2-fold change cytoplasm  nucleus = 0.13) and the
opposing trend (~12% change) in the WT (WT cytoplasm =
4.28, WT nucleus = 4.46; p < 0.0001, log2-fold change =
0.18.). The percentage of area containing a FOS signal was

(F) FGF13 fluorescence intensity (log2 pixel intensity/area), with small dots representing cells and large dots averaged by animal (WT: n = 3, 92, 45, and 71 cells;
KO: n = 5, 69, 19, 41, 99, and 69 cells). Lines represent grand means ± 95% confidence intervals.
(G–K) FGF13 area (percentage of region with an antibody signal above background) for the same cells as in (E). (G)–(I), as in (H)–(K), but for FOS immunostaining
(WT: n = 3, 68, 70, and 62 cells; KO: n = 4, 94, 53, 44, and 98). Intensity and area with signal were analyzed using linear mixed models fitting fixed effects of
subcellular localization (cytoplasm, nucleus), genotype (WT, KO), and their interaction, using individual cells per animal as a repeated-measure/random effect.
Significant effects were determined by ANOVA with Tukey post hoc multiple comparisons between means computed in R using the lsmeans package. Significant
comparisons in (D)–(K) are for p < 0.001. Scale bars in (E) and (I) represent 10 mm as indicated.
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enriched in the nucleus of WT animals (Figure 6I; ~7% higher in
the nucleus; p < 0.0001; cytoplasm = 49.4%, nucleus = 56.2%)
but enriched in the cytoplasm of KO animals (~5% higher in
the cytoplasm; p < 0.0001; cytoplasm = 54.3%, nucleus =
49.1%) The effects that are small in magnitude, however, are
both consistent with the model in which CELF6 represses
mRNA levels and protein expression in WT animals, which are
de-repressed in the cytoplasm in KO animals.
DISCUSSION
In this study, we identify the in vivo targets of CELF6 in the brain.
Our methods required us to use a tagged protein, but that protein
exhibits the endogenous expression pattern and is only
modestly overexpressed (Maloney et al., 2016). We found that
CELF6 primarily binds to 30 UTRs of mRNAs, with many targets
shared by CELF4 (Wagnon et al., 2012). UTR elements under
CELF6 CLIP peaks are enriched for several motifs previously
identified (Ray et al., 2013) and are similar to CELF1 preferences
(Wang et al., 2015). Using PTRE-seq (Cottrell et al., 2018), we
evaluated the effect of CELF6 across many binding elements.
Although our in vitro assays are not direct binding assays, we
show that CELF6 and other CELFs are associated with downregulation of target 30 UTRs, and this can be mitigated by motif mutation. Future work on this protein will involve understanding its
binding affinity and effect on mRNA half-life. Although CELF6
has been shown to regulate alternative splicing (Ladd et al.,
2004), we find very few significant targets outside of 30 UTR regions, suggesting that CELF6 in the brain may be more involved
with post-transcriptional regulation. UTR binding is consistent
with recent work showing CELF6 is able to regulate the stability
of p21 (Liu et al., 2019) and FBP (Yang et al., 2020) in cancer
cells. We found very few changes to splicing in Celf6 KO mice
(not shown; available at GEO: GSE160293) and few effects to
TE, suggesting that CELF6 acts on its brain targets primarily to
enhance mRNA degradation. We show these same targets are
regulated in vivo and that loss of CELF6 can alter both protein intensity and subcellular distribution.
Our work here raises a number of biological questions.
Although most of the PTRE-seq library was repressive, many elements were not further sensitive to CELF6 expression. This
suggests that either CELF6 has additional functions on these
transcripts not assayed (e.g., RNA localization) or that its functional effect on these sequences depends on cellular context.
Although CELF2-6 RNA levels were largely undetectable in SHSY5Y cells, the complement of other RBPs certainly differs
from that of neurons. We did detect levels of MBNL1 in SHSY5Y cells, an RBP that has been shown to antagonize CELF1
(Wang et al., 2015) leading to mRNA stabilization. It has also
been shown that CELF1, CELF2, and CELF6 can all antagonize
MBNL1’s splicing functions (Ohsawa et al., 2015). If MBNL1
and CELF6 can act antagonistically, then the resistance to
CELF6 of some constructs in culture may be due to MBNL1
expression. Antagonistic activity of RBPs on mRNA translation
and stability has also been observed for CELF2 and HUR (Sureban et al., 2007) and ELAVL1 and ZFP36 (Mukherjee et al., 2014).
Such activity between RBPs may be mediated by binding-site
proximity, and when RBP levels are altered, access to sites
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changes, and so does regulation (see Plass et al., 2017, study
of AU-rich elements). In our analysis of CELF6 CLIP targets,
we found enriched binding motifs across several RBP families.
Future work will explore how interactions between sequence elements affects target CELF sensitivity.
It may be that CELF6-association downregulation of targets is
due to enhancement of mRNA decay. Indeed, CELF1 has been
shown able to recruit poly(A) ribonuclease (PARN) to RNA targets
to facilitate mRNA decay, and Moraes et al (2006) found that
CELF1 could associate with PARN in vitro. We tested co-immunoprecipitations of CELF6 with PARN but did not find evidence
of an association in vitro (data not shown). However, it may associate with other proteins that mediate decay. The Xenopus homolog of the CELF proteins, EDEN-BP, has also been shown
to regulate deadenylation, and oligomerization of the protein is
required for that activity (Cosson et al., 2006). Future work will
also explore whether CELF interactions (homo- or heterodimers)
exist and can affect regulation. Finally, structure-function analysis mapping the domains involved in any such interactions will
be of great interest in future studies.
CELF6 target enrichment for synaptic mRNAs and altered
localization of FOS and FGF13 make it interesting to speculate
that there is a role for CELF6 in regulating neuronal mRNA localization. Neurons are known to carefully regulate localization near
activated spines to allow local translation to influence the development and strength of synaptic connections. However,
because CELF6 expression is limited to sparse populations of
neuronal cells poorly characterized with respect to local mRNA
regulation, foundational work will be required before that can
be fully assessed.
In sum, we have presented identification of CELF6 CNS binding targets in vivo and show that CELF6 can regulate mRNA
abundance, both in vitro and in vivo. Some of these targets
may mediate the behavioral phenotypes of the CELF6 KO
mouse, which include communicative, exploratory, and reward
system deficits (Dougherty et al., 2013; Maloney et al., 2019).
Robust changes in response to more modest changes in RNA
abundance indicate that mRNA translation must be carefully
tuned for normal brain function and that subtle disruption of
mRNA levels can substantially change the organism. Our data
present an opportunity for further investigation into which targets, in which cell types, can regulate behavior.
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Clone 19F7; RRID: AB_2716736
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Clone 19C8; RRID: AB_2716737

Chicken anti-GFP
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MilliporeSigma
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Geoffrey Pitt lab

N/A
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Horseradish Peroxidase Goat anti-chicken IgY
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H-1004; RRID: AB_2313517

New England Biolabs

C2987

Antibodies

Bacterial Strains
NEB 5-alpha Competent E. coli (High Efficiency)
Deposited Data
CLIP-Seq raw data

This paper

GEO: GSE118623

PTRE-Seq raw data

This paper

GEO: GSE118623

ATCC

CRL-2266

Experimental Models: Cell Lines
Human: SH-SY5Y (female, age 4 years)
Experimental Models: Organisms/Strains
Mouse: CELF6-HA/YFP

Dougherty Lab

JD2078

Mouse: Celf6/ (‘‘KO’’)

Dougherty Lab

Brj56

Integrated DNA Technologies

N/A

His/Xpress-CELF3 plasmid

Thomas Cooper lab

N/A

His/Xpress-CELF4 plasmid

Thomas Cooper lab

N/A

His/Xpress-CELF5 plasmid

Thomas Cooper lab

N/A

His/Xpress-CELF6 plasmid

Thomas Cooper lab

N/A

EGFP-CELF6

This paper

N/A

pEGFP-C1

Clontech

N/A

pcDNA3.1 His-A

Thermo Fisher

V38520

EGFP-RPL10a

Heiman et al., 2008

N/A

Oligonucleotides
See Table S9
Recombinant DNA

pQC membrane TdTomato IX

Addgene

37351

pmrPTRE-AAV

This paper

N/A

pmrPTRE-AAV with CELF6 CLIP target UTR library

This paper

N/A

Trimmomatic

Bolger et al., 2014

http://www.usadellab.org/cms/?
page=trimmomatic

STAR

Dobin et al., 2013

https://github.com/alexdobin/STAR

FGBio

Fulcrum Genomics

https://github.com/fulcrumgenomics/fgbio

Software and Algorithms

Picard Tools

Broad Institute

https://broadinstitute.github.io/picard

Samtools

Li et al., 2009

http://samtools.sourceforge.net/

Bedtools

Quinlan and Hall, 2010

https://github.com/arq5x/bedtools2/blob/master/
docs/content/overview.rst

Piranha

Uren et al., 2012

http://smithlabresearch.org/software/piranha/
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Subread (featureCounts for read counting)

Liao et al., 2013

http://subread.sourceforge.net/

R

R Core Team, 2014

https://www.r-project.org/

edgeR (R package)

Robinson et al., 2010

https://bioconductor.org/packages/release/bioc/
html/edgeR.html

Discriminative Regular Expression Motif Elicitation
(DREME)

Bailey, 2011

http://meme-suite.org/tools/dreme

Analysis of Motif Enrichment (AME)

McLeay and Bailey, 2010

http://meme-suite.org/tools/ame

Find Individual Motif Occurences (FIMO)

Grant et al., 2011

http://meme-suite.org/tools/fimo

CISBP-RNA Database: Catalog of Inferred
Sequence Binding Preferences of RNA binding
proteins

Ray et al., 2013

http://cisbp-rna.ccbr.utoronto.ca/index.php

lme4 (R package)

Bates et al., 2015

https://cran.r-project.org/web/packages/lme4/
index.html

multcomp (R package)

Hothorn et al., 2008

https://cran.r-project.org/web/packages/
multcomp/index.html

car (R package)

Fox and Weisberg, 2019

https://cran.r-project.org/web/packages/car/
index.html

limma (R package)

Ritchie et al., 2015

https://bioconductor.org/packages/release/bioc/
html/limma.html

ImageJ

NIH

https://imagej.nih.gov/

lsmeans (R package)

Lenth, 2016

https://cran.r-project.org/web/packages/lsmeans/

RESOURCE AVAILABILITY
Lead Contact
Requests for information, resources, and reagents should be directed to Joseph D. Dougherty (jdougherty@genetics.wustl.edu).
Materials Availability
Materials are available as found above in the Key Resources Table. Plasmids generated in this study (pmrPTRE-AAV, pmrPTRE-AAV
with CELF6 target UTR library), please see Lead Contact above. Raw sequencing data, as well as processing and analysis code, can
be found under Data and Code Availability.
Data and Code Availability
All software packages can be found in Key Resources Table. Raw and processed sequencing data from CLIP-Seq can be accessed
through the National Center for Biotechnology Information’s Gene Expression Omnibus under accession number GSE118623. UCSC
Genome Browser session showing CLIP-Seq data associated with NCBI GEO Accession GSE118623 can be viewed following this
link:
http://genome.ucsc.edu/cgi-bin/hgTracks?
hgS_doOtherUser=submit&hgS_otherUserName=mrieger&hgS_otherUserSessionName=celf6_clip_mm10
Code used to call peaks, perform MEME-SUITE motif enrichment clustering, and analyze the PTRE-Seq library data can be found at:
https://github.com/clevermizo/CELF6CLIPMS
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal Models
All protocols involving animals were approved by the Animal Studies Committee of Washington University in St. Louis. Cages were
maintained by our facility on a 12 hr: 12 hr light:dark schedule with food and water supplied ad libidum.
Genotyping
Genotyping of all mice was performed using a standard protocol. Animals were genotyped from toe clip tissue lysed by incubation at
50 C in Tail Lysis Buffer for 1 h to overnight (0.5 M Tris-HCl pH 8.8, 0.25 M EDTA, 0.5% Tween-20) containing 4 mL/mL 600 U/mL
Proteinase K enzyme (EZ BioResearch), followed by heat denaturation at 99 C for 10 min. 1 mL Crude lysis buffer was used as template for PCR with 500 nM forward and reverse primers, as specified, using 1X Quickload Taq Mastermix (New England Biolabs) with
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the following cycling conditions: 94 C 1 min, (94 C 30 s, 60 C 30 s, 68 C 30 s) x 30 cycles, 68 C 5 min, 10 C hold. All referenced PCR
primer sequences listed below are found in Table S9.
Mice for CLIP
Mice used in CLIP experiments derived from 4 litters of CELF6-HA/YFP x C57BL6/J crosses. Each sample used for sequencing was
generated by pooling tissue from 3-4 CELF6-HA/YFP+ animals or WT animals from each litter. Pooling tissue was required to generate
sufficient material for successful CLIP library generation. Genotyping was performed using HA-F/YFP-R pair (presence or absence of
HA-YFP cassette) and Actb-F/Actb-R pair (internal PCR control). Genotyping was performed on post-natal day 7 to select animals for
pools, and then performed again on tissue collected after sample processing on post-natal day 9 to confirm genotypes. Sex of animals
was noted but not controlled in statistical analysis of CLIP-Seq data as all pools contained animals of both sexes.
(1) Litter 1: 8 total animals.
CELF6-HA/YFP Pool 1: 4 animals: 1 male and 3 females.
CTL Pool 1: 4 animals: 3 males and 1 female.
(2) Litter 2: 8 total animals.
CELF6-HA/YFP Pool 2: 4 animals: 2 males and 2 females.
CTL Pool from this litter was excluded because upon confirmatory regenotyping it was determined that 1 CTL animal in the pool
was actually CELF6-HA/YFP+.
(3) Litter 3: 6 total animals.
CELF6-HA/YFP Pool 3: 3 animals: 2 females and 1 male.
CTL Pool 2: 3 animals: 2 males and 1 female.
(4) Litter 4: 8 total animals.
CELF6-HA/YFP Pool 4: 4 animals: 2 females, 2 males.
CTL Pool 3: 4 animals: 3 males, 1 female.
Mice for Agilent Expression microarray
8 Celf6+/+ (WT) (3 males and 5 females) and 8 Celf6/ (KO) animals (4 males and 4 females) derived from 13 litters of Celf6+/ X
Celf6+/ crosses were used to generate tissue for the RNA microarray experiment used to assay expression of CELF6 CLIP targets.
Animals were genotyped as above using Celf6genoF/Celf6genoR primer pair and age when tissue was harvested ranged between
3.5-9 months.
Cell Culture
SH-SY5Y neuroblastoma cells (ATCC CRL-2266) were maintained at 5% CO2, 37 C, 95% relative humidity in 1:1 Dulbecco Modified
Eagle Medium/Nutrient Mixture F-12 (DMEM/F12 GIBCO) supplemented with 10% fetal bovine serum (FBS Sigma). Under maintenance conditions, cells were also incubated with 1% Penicillin-streptomycin (Thermo), but antibiotics were not used during transient
transfections. Cell passage was performed with 0.25% Trypsin-EDTA (Thermo).
METHOD DETAILS
CLIP
Our CLIP procedure is modeled after the procedure of Wang et al. (2015). Post-natal day 9 mice were euthanized by rapid decapitation, and brains were dissected. Cortices and cerebella were removed, retaining basal forebrain, striatum, diencephalon, colliculi, and hindbrain regions, which are the brain regions with highest CELF6 expression (9). Dissected tissue was flash frozen in
liquid nitrogen and then powdered with a mortar and pestle cooled with liquid nitrogen and kept on dry ice in 10 cm Petri dishes
until use. Crosslinking was performed using 3 rounds of 400 mJ/cm2 dosage of 254 nm ultraviolet radiation, with Petri dishes on dry
ice, in a Stratalinker UV crosslinker. After each round of crosslinking, powder in the dishes was redistributed to allow for even
crosslinking. After crosslinking, powders were kept on wet ice and incubated with 1mL lysis buffer (50 mM Tris-HCl pH 7.4,
100 mM NaCl, 1X cOmplete EDTA-free protease inhibitor (Sigma), 0.04 U/mL recombinant RNasin (Promega), 10 mM activated sodium orthovanadate, 10 mM NaF). Recombinant RNasin does not inhibit RNase I which was used for RNase digestion in CLIP and
was added to prevent other environmental RNase activity. To obtain both cytoplasmic and nuclear fractions in the lysate, lysis
buffer was supplemented with NP40 (Sigma CA630) detergent (final concentration 1%) and subjected to mechanical homogenization in a teflon homogenizer 10 times, and lysates were allowed to incubate on ice for 5 min. For RNase digestion, RNase If (New
England Biolabs) was diluted to final concentration 0.5, 0.1, or 0.05 U/mL per lysate for radiolabeling. For control radiolabeled samples (no crosslink and WT tissue immunoprecipitates), the highest (0.5 U/mL) concentration of RNase was used. For samples used
for sequencing, 0.05 U/mL final concentration was used. RNase-containing lysates were incubated in a thermomixer set to 1200
RPM at 37 C for 3 min and then clarified at 20,000 xg for 20 min. 2% input lysate was saved for input samples for sequencing. Per
immunoprecipitation, 120 mL of Dynabeads M280 streptavidin (Thermo) were incubated with 17 mL 1 mg/mL biotinylated Protein L
(Thermo), and 36 mg each of mouse anti-EGFP clones 19F7 and 19C8 antibodies (MSKCC) for 1 h. Beads were prepared in batch
for all immunoprecipitations and then washed five times with 0.5% IgG-free bovine serum albumin (Jackson Immunoresearch) in 1X
PBS, followed by three washes in lysis buffer. Clarified lysates were incubated with coated, washed beads for 2 h at 4 C with
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end-over-end rotation and then washed in 1 mL of wash buffer (50 mM Tris-HCl pH 7.4, 350 mM NaCl, 1% NP-40, 0.04U/mL RNasin) four times, for 5 min with end-over-end rotation at 4 C. For radiolabeling experiments, 60% of washed bead volume was
reserved for immunoblotting and added to 20 mL of 1X Bolt-LDS non-reducing sample buffer (Thermo), and 40% proceeded to
radioactive labeling. Beads for radioactive labeling were subsequently washed 3x200 mL in PNK wash buffer (20 mM Tris-HCl
pH 7.4, 10 mM MgCl2, 0.2% Tween-20, 2.5 U/mL RNasin) and then incubated with 10 mL PNK reaction mixture (1X PNK reaction
buffer (New England Biolabs), 4 mCi g32P-ATP (Perkin Elmer), 10 U T4 PNK (New England Biolabs)) for 5 min, at 37 C. After labeling,
samples were washed in 3x200 mL PNK wash buffer to remove unincorporated label, and then added to 10 mL of 1X Bolt LDS nonreducing sample buffer. All samples in sample buffer were heated for 10 min at 70 C and then separated on a 4%–12% gradient
NuPAGE Bis/Tris gels (Thermo) and then transferred to PVDF membranes with 10% methanol for 6 h at constant 150 mA. Samples
for immunoblot were blocked for 1 h in block solution (5% nonfat dried milk in 0.5% Tween-20/1X TBS), and then overnight with
1:1000 chicken anti-GFP antibodies (AVES) with rocking at 4 C. Blots were washed 3 times for 5 min in 0.5% Tween20/1X TBS and
then incubated with 1:5000 anti-chicken HRP secondary antibodies (AVES) for 1 h at room temperature and treated with Biorad
Clarity enhanced chemiluminescence reagents for 5 min and chemiluminescent data acquired with a Thermo MyECL instrument.
Radioactive signal was acquired using an Amersham Typhoon Imaging System and a BAS Storage Phosphor screen (GE Healthcare Life Sciences).
CLIP-Seq Sequencing Library Preparation
For CLIP-Seq, EGFP immunoprecipitated WT and HA-YFP+ tissue and 2% input samples were purified from PVDF membranes as
follows. Membrane slices were cut with a clean razor according to the diagram in Figure 1A, from unlabeled samples as has been
performed in eCLIP (14). PVDF membrane slices were incubated in 1.7 mL microcentrifuge tubes with 200 mL Proteinase K buffer
(100 mM Tris-HCl pH 7.4, 50 mM NaCl, 10 mM EDTA, 1% Triton X-100) containing 40 mL of 800 U/mL Proteinase K (NEB) and incubated in a horizontal shaker at 250 RPM, 37 C for 1 h. Horizontal shaking reduces the need to cut the membrane into small pieces per
sample which is seen in many protocols, and 1% Triton X-100 in the Proteinase K buffer facilitates increased yield from the membrane
by preventing binding of Proteinase K to the membrane. 200 mL of fresh 7M Urea/Proteinase K buffer was then added to slices, and
tubes were incubated an additional 20 min with horizontal shaking at 250 RPM, 37 C. RNA was purified by addition of 400 mL of acid
phenol/chloroform/isoamyl alcohol and shaken vigorously for 15 s and allowed to incubate 5 min on the bench. RNA samples were
centrifuged at 20,000 xg for 10 min. Aqueous layers were purified using a Zymo RNA Clean and Concentrator-5 column. Output from
CLIP RNA samples was estimated for total concentration using an Agilent Bioanalyzer, and approximately 0.5 ng of RNA was used to
prepare next generation sequencing libraries. The full protocol for sequencing library preparation is given in Methods S1. Although
this protocol is based on eCLIP, Methods S1 is generalized for any RNA-Seq preparation.
Total RNA-Seq of SH-SY5Y cells
For preliminary RNA-Seq of SH-SY5Y cells, eight replicate sub-confluent (approximately 80%) 10 cm dishes (TPP) were harvested by
dissociation from the plate by pipetting and centrifugation at 500 x g, 5 min at room temperature. Pellets were lysed according to
TRAP protocol lysis conditions (Methods S2), and RNA was purified using Trizol LS, followed by treatment for 15 min at 37 C with
DNase I (NEB) and cleanup using Zymo RNA Clean and Concentrator-5 columns (Zymo Research). RNA samples were assessed
by Agilent TapeStation with RINe values between 8-10. RNA was fragmented and prepared into libraries for next generation
sequencing using Methods S1 as for CLIP-Seq samples.
Total RNA-Seq and CLIP-Seq Raw Data Processing
As all total CLIP-Seq and Total RNA-Seq samples were prepared using a unified library preparation procedure, raw data processing
used the same set of methods and tools (see Key Resources Table) for strand-specific quantification of sequencing reads containing
unique molecular identifiers (See Methods S1) to collapse amplification duplicates. Briefly, CLIP libraries were sequenced in a 2 3 40
paired-end mode on an Illumina Next-Seq. Unique Molecular Identifier (UMI) sequences were extracted from Illumina Read 2, and
reads were trimmed for quality using Trimmomatic. Using STAR, remaining reads were aligned to ribosomal RNA, and unalignable
reads corresponding to non-rRNA were aligned to the mm10 mouse reference genome and assembled into BAM formatted alignment files. BAM files were annotated with UMI information using the FGBio Java package. PCR duplicates assessed by their
UMIs were removed from the BAM files using Picard.
Peak Calling and Read Counting
To call peaks genome-wide using Piranha, the genome was windowed into 100 bp contiguous windows with 50% overlap using Bedtools, and strand-specific read counts were determined for each window. To ensure that called peaks would have the same boundaries for each replicate sample, peaks were called on a merged BAM file across all YFP-HA+ immunoprecipitated CLIP samples.
Background counts for Piranha were estimated on a gene-by-gene basis to control for differences in overall level of expression.
Piranha p values for significant peaks were adjusted for multiple testing using Benjamini-Hochberg, and all peaks called with False
Discovery Rate < 0.1 were kept for further analysis and stored as a Gene Transfer Format (GTF) file. In practice we found that Piranha
peaks varied widely, with some peaks called with widths on the order of several kilobases despite having a clear local maximum. To
more narrowly count reads near peak maxima in a consistent way across all peaks, Piranha peak boundaries were truncated to a
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width of 100 base pairs around the peak maximum. As an alternate approach for discovery, we also wanted to consider total read
counts across subgenic annotated regions (50 UTR, 30 UTR, coding sequence (CDS) and introns), for which annotations were retrieved
from the UCSC Genome Browser, in the event that CELF6 bound promiscuously without much sequence specificity though perhaps
restricted to particular region of a gene. In order to ensure correct mapping of reads to splice sites, the table of intron annotations was
allowed to overlap the surrounding exons by 10 bases. In the end, this procedure produced 5 GTF files:
d
d
d
d
d

Genome-wide peaks calls (100bp around called maxima from merged BAM file)
30 UTR
CDS
50 UTR
Introns

Each of these GTFs was used as a template for strand-specific feature counting in individual samples using the featureCounts program in the Subread package. For sums across regions (e.g., 30 UTRs) that showed enrichment in CLIP (see Quantification and Statistical Analysis below), we repeated the peak calling procedure in significantly enriched regions to determine whether any peaks
missed in the genome-wide calling could be identified locally in enriched regions. We found most significantly enriched regions,
such as 30 UTRs, had clearly definable peaks which were not determined in genome-wide peak calling. This may be due to misestimation of correct background in genome-wide calling. In genome-wide calling, background was estimated on a per-gene basis, but it
may be that peaks are still missed because a transcript model is needed for most accurate calling. Determining enriched regions and
then calling peaks on a small, localized region, seemed to ameliorate this issue.
SH-SY5Y Total RNA-seq samples were counted based on a GTF of all UCSC-annotated gene exons to derive total gene counts.
CLIP Motif Enrichment Analysis
50 bp regions under the maxima of peaks in CLIP target 30 UTRs were used in MEME Suite and compared to 50 bp regions sampled
randomly from the 30 UTRs of non-targets – genes which exhibited 0 or negative fold enrichment in YFP-HA+ CLIP samples compared
to input and WT controls. The AME tool was used to search motif enrichment against the CISBP-RNA database (Ray et al., 2013),
using the maximum match score with the ranksum test.
The position probability matrices (PPMs) for CISBP-RNA motifs showing significant enrichment in CLIP 30 UTR peaks were hierarchically clustered (Figures 2B and 2C) by using vectorized PPMs for each motif and the hclust() function in R (using the ‘‘complete’’
method). To determine whether or not there were significant matches to a cluster, rather than an individual CISBP-RNA motif PPM,
average PPMs were computed by averaging the PPMs across all cluster members. These averaged PPMs were then used with the
MEME-Suite FIMO tool to determine whether individual peaks had significant matches to each of the clusters (Tables S3 and S4).
PTRE-Seq Reporter Library Preparation
All oligos used for library preparation are provided in Key Resources Table. We generated the pmrPTRE-AAV backbone from an existing mtdTomato construct by PCR amplification and subcloning of the following elements: CMV promoter and a T7 promoter, PCR
amplified and subcloned into the MluI restriction site of pQC membrane TdTomato IX. CMV and T7 promters were amplified from
pcDNA3.1 using pCMV_T7-F/ pCMV_T7-R and Phusion polymerase (NEB). Then, in order to add a NheI-KpnI restriction enzyme
cassette into the 30 UTR, the entire pmrPTRE-AAV plasmid was amplified (pmrPTRE_AAV_Full_F/R) and recircularized using Infusion
HD (Clontech). The correct backbone sequence of pmrPTRE-AAV was confirmed by Sanger sequencing.
Originally, 462 sequences of 120 bp were considered for cloning into the library across significant genes. These included 295 peaks
in high confidence targets (meeting enrichment against both input and non-specific IP controls, see Quantification and Statistical
Analysis), and 167 peaks in lower confidence targets showing enrichment only over input. Mutations to motifs found by AME
were made as follows. The location of significant matches to motifs were determined using FIMO. Next, for each matched motif,
the PPM representing this motif in CISBP-RNA was used to determine the choice of mutation at each base. Bases showing PPM
probability of 0.8 or greater were mutated to the base showing the minimum value of PPM at that position. If all other three bases
showed equal probability, a base was randomly selected from the three. The procedure was repeated at each position for each motif
match, before moving to the next matching motif. Where motifs overlapped, lower ranking motifs (based on FIMO score) did not override mutations already made based on higher ranking motifs. After completion, this generated a set of 473 mutant elements which
ranged between 1 - 25 mutated nucleotides. Subsequently, sequences were scanned for poly A signals and restriction enzyme sites
which would interfere with cloning (NheI, KpnI), which were removed. A final set of 410 sequences (254 high confidence, 156 meeting
only input control criterion) and their paired mutant sequences were synthesized by Agilent Technologies with 120bp of UTR
sequence in addition six unique 9 bp barcodes per sequence and priming sites for amplification and cloning (final length 210 bp).
These sequences and their mutated forms are given in Table S5.
Obtained synthesized sequences were amplified with 4 cycles of PCR using Phusion polymerase with primers GFP-F and GFP-R.
We selected these priming sites as these are standard primers in our laboratory used for genotyping that result in robust amplification. The library was PAGE purified and concentration of recovered library was estimated by Agilent TapeStation. The library was
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digested with NheI and KpnI enzymes and ligated into pmrPTRE-AAV with T4 Ligase (Enzymatics). In order to ensure high likelihood
of obtaining all library elements, we prepared our plasmid pool from approximately 40,000 colonies.
PTRE-Seq Reporter Library Transfection
His/Xpress-tagged CELF3,4,5,&6 were obtained from the laboratory of Thomas Cooper. For the four-plasmid experiments, 2500 ng
containing equimolar amounts of two His/Xpress-CELF constructs, an EGFP-RPL10a construct, and the CELF6 PTRE-Seq library
were prepared with Lipofectamine 2000 in Opti-MEM I (GIBCO). For three-plasmid experiments, remaining mass was substituted
with empty pcDNA3.1-His. SH-SY5Y cells were trypsinized and incubated in 10 cm dishes with Lipofectamine/DNA complexes
overnight in DMEM/F12 supplemented with 10% FBS. The following day media was replaced with fresh DMEM/F12 supplemented
with 10% FBS. Cells were pelleted for Translating Ribosome Affinity Purification (TRAP) and total RNA extraction 40 h post-transfection. TRAP and total RNA extraction were performed according to the Methods S2. RNA quality was assessed by Agilent TapeStation, and all samples had RINe values > 8. The procedure for TRAP in Methods S2 is based on (Heiman et al., 2008) with additional
modifications that have been optimized in our laboratory. Five replicates per condition were generated in batches balanced for all
conditions. In each case, replicates were transfected from newly thawed aliquots of cells passaged once before transfection to control for cell passage. Read counts from one batch were found to cluster separately from all others after sequencing, and data from this
batch were excluded. The final data were analyzed from four replicates per condition.
PTRE-Seq Sequencing Library Preparation
PTRE-Seq sequencing libraries were prepared by cDNA synthesis using pmrPTRE-AAV antisense oligo for library specific priming,
and Superscript III Reverse Transcriptase (Thermo) according to the protocol shown in Methods S3. After cDNA synthesis, cDNA
libraries were enriched with PCR using Phusion polymerase (Thermo), and pmrPTRE-AAV antisense and sense oligos using 18 cycles. In parallel, plasmid pool DNA was also amplified for sequencing the original plasmid pool. Purified PCR products were digested
with NheI and KpnI enzymes and ligated to 4 equimolar staggered adapters to provide sequence diversity for sequencing on the
NextSeq. Ligated products were amplified with Illumina primers as in CLIP-Seq library preparation (Methods S1) and subjected to
2x40 paired-end next generation sequencing on an Illumina NextSeq.
RT-PCR and qRT-PCR
To confirm exogenous expression of CELF constructs used in PTRE-Seq experiments, 20 ng of total RNA was converted into cDNA
using qScript cDNA synthesis kit (Quantabio, kit employs a mix of both oligo-dT and random hexamer priming) and diluted 4-fold. For
RT-PCR, 4 mL of diluted cDNA was used in PCR reactions with 500 nM forward and reverse primers, (Figure S2; Table S9), using 1X
Quickload Taq Mastermix (New England Biolabs) with the following cycling conditions: 94 C 1 min, (94 C 30 s, 60 C 30 s, 68 C 30 s) x
25 cycles, 68 C 5 min, 10 C hold, and then separated by 2% agarose and stained with ethidium bromide. For qRT-PCR, 4 mL of diluted
cDNA was combined with 500 nM His/Xpress-pcDNA-F and His/Xpress-pcDNA-R primers or HsActb-F/HsAcb-R, and 1X PowerUP
SYBR Green Master Mix (Thermo). Each sample/primer combination was run in 4 technical replicates on a Viia7 Real Time PCR System (Thermo) using the following cycling program: 50 C 2 min, 95 C 2 min (95 C 1 s, 60 C 30 s) x 40 cycles, followed by dissociation
step: 95 C 15 s 1.6 /s ramp,60 C 1 min 1.6 /s ramp, 95 C 15 s 0.15 /s ramp. Samples were run alongside no template and no reverse
transcription controls to ensure reactions were free of non-target contamination, and dissociation curves were inspected to ensure the
absence of non-target amplicons. CT values for each sample were averaged across technical replicates and transformed by first
computing the DCT: = CTHis/Xpress - CTHsActb, and then computing relative log2 expression (‘‘DDCT’’): = - (DCTsample - DCTreference), where
the reference was taken to be the average DCT across the CELF6 expression condition.
PTRE-Seq Reporter Validation
For validation of individual library element reporters (Figure 4), CELF6 CDS was subcloned from His/Xpress-CELF6 into pEGFP-C1
using EcoRI and BamHI restriction sites. Individual Vat1l, Hap1, Peg3, Epm2aip1, and Rab18 reference and mutant sequences
were synthesized using Integrated DNA Technologies (IDT) gBlocks Gene Fragments and cloned into pmrPTRE-AAV with NheI
and KpnI as above.
50 ng equimolar library element reporters with either pEGFP-C1 (EGFP alone) or EGFP-CELF6 was transiently transfected into SHSY5Y cells in 96-well plates (TPP). 40 h post-transfection, media was removed and replaced with warm PBS (1.8 mM KH2PO4, 10 mM
Na2HPO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4). tdTomato and GFP fluorescence were determined by BioTek Instruments Cytation 5
Cell Imaging Multi-Mode Reader with internal temperature maintained at 37 C. 96-well plates were prepared in four replicate
batches, where each 96-well plate contained one replicate well for all 20 conditions (five reference, five mutant reporters, in both
EGFP-CELF6 and EGFP-only transfections). Log2-transformed fluorescence intensity measurements were z-score normalized on
each plate to account for batch-to-batch differences in transfection efficiency and fluorescence intensity. Data in Figure 4 are shown
further normalized to the average value for each reporter in the EGFP-only, reference sequence condition. Example epifluorescent
images were obtained using a Leica DMI3000 B microscope with 20X magnification. Monochromatic images were acquired with
QCapture software (QImaging), using gain = 1, offset = 1, exposure = 205 ms for both red and green fluorescent filter sets. 16-bit
grayscale images were converted to RGB color and minimally brightness-adjusted for presentation using Adobe Photoshop CS2.
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Agilent Gene Microarray
Brains from eight WT and eight Celf6 mutant mice (see) were extracted, frozen in liquid nitrogen, and crushed into a fine powder, from
which RNA was extracted using QIAGEN RNEasy columns on a Qiacube robot, following manufacturer’s protocol. RNA was DNase I
treated, and RNA quantity and integrity were confirmed using Agilent Bioanalyzer. cDNA was prepared and chemically labeled with
Kreatech ULS RNA labeling kit (Kreatech Diagnostics) and Cy5-labeled cDNAs were hybridized to Agilent Mouse v2 4x44K microarrays (G4846A-026655). Hybridization of the labeled cDNAs was done in Agilent 2x gene expression hybridization buffer, Agilent
10x blocking reagent and Kreatech Kreablock onto Agilent 4x44K V2 microarrays at 65 C for 20 min. Slides were scanned on an Agilent C-class Microarray scanner. Gridding and analysis of images was performed using Agilent Feature Extraction V11.5.1.1.
FGF13 and FOS Immunofluorescence
3 Celf6+/+ (WT) (2 males and 1 female) and 3 Celf6 / (KO) animals (2 males and 1 female) derived from 2 litters of Celf6+/ X Celf6
± crosses were used to generate tissue for immunofluorescence. Mice were perfused with PBS followed by 4% paraformaldehyde(PFA) in PBS. Brains were dissected then post-fixed overnight in 4% PFA, cryoprotected in increasing concentrations of sucrose
over 48 h, and frozen in blocks of OCT (Tissue-Tek), sectioned on a cryostat to 40 microns, and stored at 4 C in PBS/0.25% Sodium
Azide until use. Sections were blocked with 5% serum for 1h at room temperature, immersion-stained with primary antibodies overnight at room temp, washed 3x with PBS, then incubated with appropriate Alexa Fluor-labeled secondary antibodies for 90 min,
counterstained with DAPI, and sections mounted on slides. Primary antibodies included rabbit anti-FGF13 (a gift from Geoffrey
Pitt) and mouse anti-TH. Primary antibodies for FOS stain included goat anti-cFos, and mouse anti-TH (see Key Resources Table).
Immunofluorescent imaging was conducted by an experimenter blind to genotype, focusing on the locus coeruleus (as identified by
TH staining) using a Zeiss LSM 510 laser-scanning confocal microscope and accompanying software.
QUANTIFICATION AND STATISTICAL ANALYSIS
Defining CELF6 CLIP Targets by Differential Expression Analysis
Currently there is no standard statistical approach for identification of targets from CLIP data. Methods typically include clustering
aligned sequences within individual CLIP RNA samples or replicate averages, with varying probabilistic modeling approaches for
assessing signal-to-noise in read density, but rarely take into account variance across replicates or differential abundance compared
to control samples (Ascano et al., 2012; Corcoran et al., 2011; Kishore et al., 2011; Lebedeva et al., 2011; Memczak et al., 2013;
Moore et al., 2014; Mukherjee et al., 2011; Sugimoto et al., 2012; Ule et al., 2003; Wang et al., 2015; Zhang and Darnell, 2011). Furthermore, CLIP studies frequently fail to account for differences in the starting abundance of possible target mRNAs, thus reported targets are frequently biased toward highly expressed genes (Ouwenga and Dougherty, 2015). Here, we adopted a strategy of counting
reads (as described above) and using standard differential expression analysis tools (edgeR) to make statistical inference on counted
features in target immunoprecipitated samples compared to controls, with the hypothesis being that true targets will be enriched in
target HA-YFP CLIP samples over both WT controls (representing non-specific immunoprecipitation pull down) and input samples
(accounting for differences in starting abundance of possible target mRNAs). WT controls are a key recommendation in discussion of
CLIP methods using engineered tags (Van Nostrand et al., 2017).
Samples counted using Subread were imported into R using edgeR. To be included in differential analysis, counted regions were
required to possess a minimum of 10 read counts in at least 3 samples. Differential testing was then performed in edgeR against read
counts deriving from WT samples or YFP-HA+ input samples. We defined CLIP targets as those having positive fold change enrichment in YFP-HA+ CLIP samples compared to both WT CLIP and input samples, with edgeR p values < 0.05 from the edgeR two sample negative binomial exact test. To test less stringent cut-offs, we also examined some targets meeting p < 0.05 for just the YFP-HA
versus Input as noted in figure legends. Target peaks and gene information are found in Table S2. Analysis of enrichment for gene
ontology terms was performed in DAVID (Huang et al., 2009a, 2009b) using genes of known expression in the brain as the background list rather than the entire mouse genome.
PTRE-Seq Barcode Counting and Normalization
Barcode counts from sequencing read FASTQ files for each element were determined using a Python script. Read counts were imported into R using edgeR and converted to counts-per-million (CPM) to normalize for differences in library size. Elements showing no
counts in the DNA plasmid pool sequencing were removed. Expression was then computed as:
log 2 expression = log 2

CPMRNA
CPMDNA

Translation efficiency was computed as:
log 2 TE = log 2 expressionTRAP  log 2 expressionTotalRNA
We required that analyzed barcodes have at least 10 counts in at least four samples to be included in analysis. Additionally, we
required that all elements in the library have a minimum of three out of the original six barcodes present, and present for both reference and mutant sequences.
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PTRE-Seq Linear Mixed Model Analysis
The final set of elements after filtering on expression and numbers of barcodes was 379 across 153 unique gene UTRs, comprising
229 high confidence (meeting both input and wt/non-specific IP controls) and 150 lower confidence (meeting input control only) CLIP
targets. Individual linear mixed models were performed using lme4 fitting the following:
log2 expression ð or TE Þ e condition  sequence + ð1jsampleÞ
where barcodes were used as repeated-measures for each sample, per element. Fixed effect terms of condition referred to either: (a)
CTL or CELF6 expression for analyses in Figure 3, or (b) CTL, CELF6, CELF3, CELF4, CELF5, CELF3/6, CELF4/6, CELF5/6 for
analyses related to Figure 5. The fixed effect term of sequence was either (a) reference or (b) mutated sequence. Omnibus Analysis
of Deviance tests for significant effects of fixed effect terms were computed using type II ANOVA R with the car package with Satterthwaite degrees of freedom. Estimates of R2 were determined according to the procedure of Nakagawa and Schielzeth (2013)
which provides a simple method for obtaining these estimates from non-linear and empirical model fits in a ‘‘percentage of variance
explained’’-interpretative sense. Omnibus p values for fixed effects are also reported in Tables S6, S7, and S8 for models alongside
Benjamini-Hochberg adjusted False Discovery Rates for TRAP, input expression, and translation efficiency (TE) respectively.
Figures 3 and 5 show analysis of these across all individual models and for subsets of elements with smaller numbers of mutations
introduced (%8 or % 16) to discern whether radically mutating elements has exerted a strong effect. Because these subsets are
nested and because this bird’s-eye view analysis is pooling independently fitted models, we have assessed significance between
them using non-parametric Mann-Whitney U tests for differences between medians. Post hoc multiple comparisons significance
and confidence intervals reported for individual elements in Figures 3 and 4, in order to identify the sources of interaction, were
computed using the multcomp R package.
PTRE-Seq Validation Analysis
Validation of reporters in Figure 4 was assessed using the car package in R to compute Type II two-way ANOVA with main effects of
sequence and CELF6 exogenous expression and their interaction, with post hoc pairwise multiple comparisons determined using
multcomp.
Agilent Expression Microarray Analysis
Features were extracted with Agilent Feature Extraction software and processed with the limma package in R to background correct
(using normexp) and quantile normalize between arrays. Genotype of knockout samples was confirmed via decrease of Celf6 mRNA
expression level, and differential expression analysis was conducted using limma with empirical bayes (eBayes) analysis. Log2 fold
change of CLIP targets was compared to an equivalent number of randomly sampled probes by Welch’s t test. Gene Ontologies
Analysis was conducted in Cytoscape using the BiNGO Module (Maere et al., 2005), with Benjamini-Hochberg correction and a
display cutoff of p < 0.01. Cellular component results are displayed.
Immunofluorescence Quantification
Positive FOS and FGF13 immunofluorescent signal was quantified using the NIH Image analysis software, ImageJ. Cell bodies and
nuclei were demarcated via freehand outlining by experimenter blind to genotype based on TH and DAPI stain of cells. Intensity of
signal was measured in each cell, as well as within the nucleus of each cell, and normalized by total pixel area. Fraction of area containing positive signal in each cell and within each nuclei were also measured using a standardized threshold for positive signal.
Signal intensity/area as well as fraction of area containing signal for each protein was analyzed using a linear mixed effects model
in R with lme4, with individual quantified regions of interest as a repeated-measure for each animal, with fixed effects of region (cytoplasm versus nucleus) and genotype (WT versus KO). Significance was determined using Type II ANOVA with Satterthwaite degrees
of freedom using the car package in R, with post hoc multiple pairwise comparisons determined using the multcomp package.
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Sample

yfp-1-ip
wt-1-ip
yfp-1input
wt-1input
yfp-2-ip
wt-2-ip
yfp-2input
wt-2input
yfp-3-ip
yfp-3input
yfp-4-ip
wt-3-ip
yfp-4input
wt-3input

Genotype Fraction total
pairs
(millions)
yfp
ip
9.9
wt
ip
15.6
yfp
input
4.6

%
unique
duplication aligners
(millions)
6.59
5.9
4.64
9.7
6.15
2.7

3UTR

CDS

5UTR

introns

19.2
15.53
12.4

25.53
27.98
20.47

4.5
4.91
12.58

50.77
51.57
54.55

wt

input

4.9

6.96

2.7

13.5

19.15

11.38

55.97

yfp
wt
yfp

ip
ip
input

6.9
3.2
29.3

4.48
5.14
19.48

4.1
1.6
21.2

14.7
10.86
11.61

27
27.8
16.12

10.2
10.28
4.2

48.1
51.06
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Table S1: Sequencing results for CLIP-Seq samples, Related to Figure 1. Table showing CLIP-Seq
samples 1-4, CLIP-Seq input samples 1-4, and WT CTL IP samples 1-3 with: total read pairs (millions) surviving
quality trimming, % duplication as estimated by unique molecular identifiers, uniquely aligning reads (millions), %
of uniquely aligning reads aligning to 3’UTR, CDS, 5’UTR, or intronic subgenic regions.
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Figure S1: Proximity of CELF6 CLIP peaks to poly-adenylation sites, Related to Figure 1. (A) Length
distribution of 3’ UTRs of putative CELF6 CLIP-targets (N=544) (left, red) and length distribution of 3’ UTRs
from control genes showing no enrichment or depletion in CELF6 CLIP compared to immunoprecipitates
from WT littermate controls and CELF6-YFP input samples (randomly selected length-matched, N=544).
(B) Read depth around poly-adenylation (AATAAA or ATTAAA) signals in CELF6 CLIP or control UTRs. (C)
Number of polyA sites per UTR in CELF6 CLIP-targets or length-matched controls for either AATAAA/ATTAAA (left) or AATAAA and ATTAAA separately (right). (D) Distance from CLIP peak to closest polyA site
expressed as % of length of the UTR. Controls employed randomly selected coordinates in lieu of peaks.
(E) Same as (D) for UTRs with only a single polyA site. Significance in C-E tested determined by t-test.
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Figure S2: Expression of His/Xpress-tagged CELF constructs in PTRE-Seq replicates,
Related to Figure 3 and Figure 5.
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Figure S2: Expression of His/Xpress-tagged CELF constructs in PTRE-Seq replicates, Related to Figure
3 and Figure 5. CELF6 CLIP UTR element PTRE-Seq library was transiently expressed in neuroblastoma SHSY5Y along with EGFP-RPL10a and the following constructs: pcDNA3.1 (CTL), (C6), His/Xpress-CELF3 (C3),
His/Xpress-CELF4 (C4), His/Xpress-CELF5 (C5). Constructs were transfected singly or in combination with
His/Xpress-CELF6, and exogenous expression was confirmed by RT-PCR with 25 cycles, using primers for
CELF1-6, His-Xpress tag, or ACTB as a loading control, separated by 2% agarose, and stained with ethidium
bromide. Results shown from (A) Replicate set #1, (B) Replicate set #2, (C) Replicate set #3, (D) Replicate set
#4. (E) Quantitative real-time PCR (40 cycles) showing log2 expression level of constructs (relative to ACTB),
using the His-Xpress tag primer set across conditions, and normalized to the average of the C6 condition. 2 out
of 4 CTL samples showed amplification with His/Xpress tag primers in excess of 35 cycles, the remaining 2
samples did not show any amplification. Points show individual sample values and lines show means.
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Figure S3: Gene Ontology of Up-regulated Genes in CELF6 KO brain, Related to Figure 6. (A)
& (B) expression of example high confidence (Fgf13, Reln) or lower stringency (Mecp2, Fos) CLIP
targets in WT and KO mouse brain (see Figure 6). (C) Gene Ontology network of 200 most upregulated transcripts (p<0.05) in CELF6 KO brain tissue highlights alterations of synaptic and transcriptional genes. Shading denoted Benjamini-Hochberg adjusted p-values for enriched GO terms. Network constructed in Cytoscope using BiNGO.

Table S9: Oligonucleotides, Related to Key Resource Table.
Mouse genotyping
Sequence (5’-3’)
Oligo Name
Amplicon Size
TTAAGCGTAGTCTGGGACGTCGTA HA-F
TGGGT
480 bp
CTACGTCCAGGAGCGCACCATCTT YFP-R
CTT
AGAGGGAAATCGTGCGTGAC
Actb-F
100 bp
CAATAGTGATGACCTGGCCGT
Actb-R
CCCTGCCACCTAGCTCTTCAGGTT Celf6geno-F
415 bp (WT), 188 bp
ATGGCTGAGCTCTTTCTTGAGAAG Celf6geno-R
(KO)
TAC
Modified eCLIP-Seq Next Generation Sequencing Library Prep
Sequence (5’-3’)
Oligo Name
Ordering Specs
/5Phos/rArGrArUrCrGrGrArArGrArGr
A01m adapter
RNase-Free HPLC
CrGrUrCrGrUrGrUrArG/3SpC3/
purification, Storage 200
μM in H2O
ACACGACGCTCTTCCGA
AR17 primer
Storage 200 μM in Tris
pH 7.8
/5Phos/NNNNNNNNNNAGATCGGAA Rand103tr3
PAGE purification,
GAGCACACGTCTG/3SpC3/
adapter
machine mixing for [N]10,
Storage 200 μM in Tris
pH 7.8
AATGATACGGCGACCACCGAGATC Illumina Universal PAGE purification,
TACACTCTTTCCCTACACGACGCT
F
Storage 100 μM in Tris
CTTCCGATC*T
pH 7.8
CAAGCAGAAGACGGCATACGAGAT Illumina R with
PAGE purification,
xxxxxxxxxGTGACTGGAGTTCAGAC
Index ([x]9)
Storage 100 μM in Tris
GTGTGCTCTTCCG*A
sequence for
pH 7.8
sample
multiplexing
PTRE-Seq Library Generation & Sequencing Library Preparation
Sequence (5’-3’)
Oligo Name
Ordering Specs
TGACACGCGTGTTGACATTGATTAT pCMV_T7-F
Storage 100 μM in Tris
TGACTAGTTA
pH 7.8
TGACGGATCCTCCCTATAGTGAGT pCMV_T7-R
“
CGTATTAATTT
TAAGCTAGCCTGGTACCGGCATCC pmrPTRE_AAV_F “
CTGTGACCCCTC
ull_F
GGTACCAGGCTAGCTTACTTGTAC pmrPTRE_AAV_F “
AGCTCGTCCATGCCGTAC
ull_R
CCTACGGCGTGCAGTGCTTCAGC
GFP-F
“
CGGCGAGCTGCACGCTGCGTCCT GFP-R
“
C
GGCACTGGAGTGGCAACT
pmrPTRE
“
antisense
GCATGGACGAGCTGTACAAG
pmrPTRE sense
“
ACACTCTTTCCCTACACGACGCTC
KpnI_overhang_1 PAGE purification,
TTCCGATCTTCATGTA*C
Storage 100 μM in Tris
pH 7.8

ACACTCTTTCCCTACACGACGCTC
TTCCGATCTCAGGTGTA*C
ACACTCTTTCCCTACACGACGCTC
TTCCGATCTGTTCCTGTA*C
ACACTCTTTCCCTACACGACGCTC
TTCCGATCTAGCAGCTGTA*C
/5phos/A*TGAAGATCGGAAGAGCGT
CGTGTAGGGAAAGAGTGT-3
/5phos/A*CCTGAGATCGGAAGAGC
GTCGTGTAGGGAAAGAGTGT-3
/5phos/A*GGAACAGATCGGAAGAG
CGTCGTGTAGGGAAAGAGTGT-3
/5phos/A*GCTGCTAGATCGGAAGA
GCGTCGTGTAGGGAAAGAGTGT-3
/5phos/C*TAGAGATCGGAAGAGCA
CACGTCTG
CAGACGTGTGCTCTTCCGATC*T

KpnI_overhang_2

“

KpnI_overhang_3

“

KpnI_overhang_4

“

KpnI_complement
_1
KpnI_complement
_2
KpnI_complement
_3
KpnI_complement
_4
NheI_overhang

“

NheI_complement

“

“
“
“
“

Table S9: Oligonucleotides, Related to Key Resource Table. Oligonucleotides for genotyping, reporter
library generation, and sequencing library preparation.

Methods S1. Generalized Library Prep with rRNA Depletion & tagging with unique molecular identifiers
(UMI), Related to Figure 1.
This protocol is based on the method found in:
Van Nostrand, Eric L., et al. "Robust transcriptome-wide discovery of RNA-binding protein binding sites with
enhanced CLIP (eCLIP)." Nature methods 13.6 (2016): 508-514.
and adapted for both CLIP-Seq & total RNA-Seq. The starting material is purified RNA.
This protocol is written presuming a strip tube format. Make sure to have a Permagen Labware strip tube
magnet, strip tube mini-centrifuge, and 10 µL 8-channel multichannel pipettor, and 300 µL 8-channel
multichannel pipettor.
rRNA Probe Annealing
Materials: NEBNext rRNA depletion kit (E6310)
RNA should be 10ng-1µg in a 12µL volume
The NEBNext rRNA depletion kit functions by hybridizing a proprietary mix of DNA probes complementary to
rRNA. RNase H then degrades RNA:DNA hybrids, leaving unhybridized RNA intact. Afterwards, DNA probes
are degraded by DNase I treatment.
1. Per reaction assemble: 1 µL NEBNext rRNA depletion solution 2 µL Probe hybridization buffer 12 µL
RNA Sample
2. Vortex and spin down.
3. Thermal cycling program (with lid at 105°C) is as follows:
95°C
2 min
95-22°C
0.1°C/sec*
22°C
5 min hold
* On our Biorad Thermal Cyclers, we have to set the following for second stage:
731 total cycles, 1 sec
95C start, -0.1deg/cycle
4. Spin and place on ice.
RNase H Digestion
1. Make a master mix. Per reaction add:
2 µL NEBNext RNase H
2 µL RNase H Reaction Buffer
1 µL H2O
2. Add 5 µL to 15 µL rRNA annealing reaction (20 µL final volume)
3. Vortex, spin, and heat to 37°C for 30 minutes with lid at 40°C
DNase I Digestion
1. Make a master mix. Per reaction add:
5 µL DNase I Reaction Buffer
2.5 µL DNase I (RNase-free)
22.5 µL H2O
2. Add 30 µL to 20 µL reaction (50 µL final volume)
3. Vortex, spin, and heat to 37°C for 30 minutes with lid at 40°C

Clean up with MyONE Silane Beads
Materials:
MyONE Silane Beads (Thermo Scientific 37002D)
Buffer RLT (Qiagen, any RNA kit or Product # 79216)
5M NaCl,100% EtOH,75% EtOH,80% EtOH (later steps in this protocol)
Strip tube magnet (Permagen Labware 0.2 mL PCR Strip Magnetic Separator)
1.7 mL tube magnet
MyONE Silane and Agencourt RNAClean are not the same technology. MyONE Silane can purify small
fragments given the right proportion of EtOH, Agencourt RNAClean bottoms out at 100 nt.
1. Separate 20 µL of MyONE Silane beads per sample on magnet and remove storage buffer. (For 10
samples, separate 200 µL, etc. Use 1.7 mL tube for batch preparation.)
2. Wash beads in batch with 900 µL of Qiagen Buffer RLT.
3. Resuspend beads in 150 µL/sample of Qiagen Buffer RLT (3 starting sample volumes) and 5 µL per
sample 5M NaCl. (For large numbers of samples, you may need to use a 15 mL conical. For 10
samples of 50 µL each, resuspend beads in 1500 µL Buffer RLT + 50 µL 5M NaCl.)
4. Split rRNA depletion reaction to two sets of strip tubes (50 µL → 25 & 25). This is to ensure strips can
accommodate total volume.
5. To each sample add. 77.5 µL Beads, RLT, NaCl with multichannel. Mix by pipetting up and down 10
times.
6. Add 154 µL 100% EtOH (1.5 mix volumes) to each strip tube with multichannel.
7. Mix by pipetting up and down and rotate samples at room temp for 15 minutes.
8. Separate on magnet for 30 seconds and remove supernatant.
9. Wash beads with 0.2 mL 75% EtOH. Pipette to fully resuspend and move to new strip. At this step,
combine strips that were split in step 4.
10. Separate on magnet for 30 seconds. Remove wash with multichannel.
11. Wash 2 more times with 75% EtOH. Add wash buffer and let sit for 30 seconds on magnet and remove
with multichannel.
12. Dry 5 minutes on magnet. Remove excess EtOH with vacuum or by pipette which may collect at bottom.
13. Resuspend in 10 µL of H2O and let sit for 5 minutes off magnet. Then to clean up put back on magnet,
separate, and move eluates to new strip tubes.
Optional: Resuspend in >10 μL and assess a small amount by Agilent TapeStation or Agilent Bioanalyzer to
confirm loss of small (18S) and large (28S) rRNA peaks.
Note: Contamination with MyONE Silane beads does not appear to inhibit any downstream steps, so don't
worry about a small amount of magnetic beads coming along.At the very end of library preparation, however,
you do want to ensure libraries are bead-free before pooling for sequencer.
Fragmentation
If doing CLIP or another prep where RNA samples are already fragmented, use mix components in step (1) and
skip to dephosphorylation reaction.
1. Per reaction assemble:
1.2 μL 10X Antarctic Phosphatase Buffer (NEB M0289)
9.3 μL rRNA-depleted sample RNA
2. Thermal cycler 94°C (lid at 105°C) for 5-15 minutes
3. Move to ice.

We did 15 minutes starting with 1 µg into rRNA depletion and had peak fragments between 80-100 nt by
TapeStation. You may want to do an experiment with trial RNA and monitor peak size of fragments with
TapeStation or Bioanalyzer (or even a RNA polyacrylamide gel). Smaller amounts probably need less
fragmentation time.
Dephosphorylation Reaction
RNase I digestion in CLIP, and heat based fragmentation for total RNA-Seq both leave 3' phosphates. These
must be removed before adapter ligation. Triton-X 100 is added to 1% based upon personal communication
with NEB Tech Support that this improves dephosphorylase activity of T4 PNK to >90%. We have not
determined empirically whether multiple dephosphorylation enzymes are really necessary.
1. Make a master mix. Per reaction add 1.5 µL of:
0.5 µL rRNasin (Promega N2511)
1 µL Antarctic Phosphatase (NEB M0289)
2. Add 1.5 µL to each sample.
3. Vortex samples briefly and spin.
4. Heat to 37°C for 30 minutes with lid at 40°C.
5. Make a master mix. Per reaction add:
2.5 µL T4 PNK Buffer
2.5 µL 10% Triton-X 100
0.5 µL T4 PNK (NEB M0201)
7.5 µL H2O
6. Add 13 µL master mix to each sample (final volume 25 µL).
7. Vortex briefly and spin down.
8. Heat to 37°C for 30 minutes with lid at 40°C
Clean up with MyONE Silane Beads (Abbreviated, see above for full protocol)
1. 20 µL of MyONE Silane beads per sample.
2. Wash beads in batch with 900 µL RLT.
3. Resuspend beads in 75 µL/sample of Qiagen Buffer RLT (3 volumes, last step is 25 µL) and 2.5
µL/sample 5M NaCl.
4. Add 77.5 µL NaCl/RLT/beads to samples & 154 µL 100%EtOH
5. Mix and rotate samples at room temp for 15 minutes.
6. Separate on magnet for 30 seconds and remove supernatant.
7. Wash with 0.2 mL 75% EtOH and move to new strip.
8. Wash 2 more times with 0.2 mL 75% EtOH.
9. Dry 5 minutes on magnet.
10. Remove residual EtOH.
11. Resuspend in 9~9.5 µL of H2O and let sit off magnet for 5 minutes.
12. Separate on magnet and move 8.5 µL eluate to strip tubes containing A01m adapter. (See next section).
Optional: Resuspend in >9 μL and assess a small amount by Agilent TapeStation to confirm size shift as a
result of fragmentation. Elution volume is slightly larger than 8.5 µL to ensure you can move volume safely to
next set of tubes.

A01m Ligation
A01m Adapter:
/5Phos/rArGrArUrCrGrGrArArGrArGrCrGrUrCrGrUrGrUrArG/3SpC3/
(IDT: Purify at 250 nmol RNA Oligo scale using RNase-Free HPLC Purification, store at 200 µM in H2O,
aliquoted, at -80° C. SpC3 is a molecule which is a carbon chain that can be added to oligos. It blocks any
ligation at its own end, since there is no 3' OH group, thus adapter chains are not possible.)
T4 RNA Ligase High Concentration (NEB M0437)
Strip tube should contain 9 µL total: 8.5 µL dephosphorylated RNA fragments & 0.5 µL 40 μM A01m.
Heat to 65°C for 2 minutes with lid at 105°C.
Place on ice for 1 minute.
Make a master mix. Per reaction add:
1.5 µL DMSO (100%)
2.0 µL RNA Ligase Buffer (10x)
2.0 µL ATP (10 mM)
0.5 µL Promega rRNasin (40 U / mL)
5. Add 6 µL mix to each sample.
6. Vortex briefly and spin down.
7. Per reaction add 4 µL PEG8K (50%). (Cut pipette tip for easier pipetting.)
8. Vortex briefly and spin down.
9. Add 1 µL T4 RNA Ligase High Conc (30 U/ µL).
10. Vortex briefly and spin down.
11. Tape down horizontally into a container and place on a shaker at 250 rpm for 2 hours at room temp.
1.
2.
3.
4.

Clean up with MyONE Silane Beads (Abbreviated, see above for full protocol)
NaCl is not added as there is NaCl in the RNA Ligase buffer. According to Eric Van Nostrand, the EtOH
percentage is changed to favor larger fragments and not unligated adapter.My own experiments with MyONE
Silane are somewhat inconclusive as to whether that matters.
1.
2.
3.
4.
5.
6.
7.
8.
9.

Separate 10 µL of MyONE Silane beads per sample.
Wash beads in batch with 900 µL of Qiagen Buffer RLT.
Resuspend beads in 60 µL/sample of Qiagen Buffer RLT.
Add 60 µL beads/RLT to each sample and mix.
Add 52.5 µL EtOH (0.75 mix volumes) and mix.
Rotate samples at room temp for 15 minutes.
Separate on magnet for 30 seconds and remove supernatant.
Wash with 0.2 mL 75% EtOH. Resuspend and move to new tube.
Separate on magnet for 30 seconds. Wash 2 more times with 75% EtOH with resuspending (30
seconds on magnet).
10. Dry 5 minutes on magnet.
11. Remove residual EtOH.
12. Resuspend in 7.5~8 µL of H2O and let sit for 5 minutes. Separate on magnet and move 7 µL to a new
set of strip tubes containing 1.5 µL of 20 μM AR17 primer.
Reverse Transcription
AR17 primer: ACACGACGCTCTTCCGA
Order as standard primer. Store in H2O at 200 μM at -20°C.

Working dilution is 20 μM.
Thermo Superscript RT III First Strand Synthesis system (Thermo 18080051)
1.
2.
3.
4.

Strip tubes should contain 1.5 µL AR17 (20 µM) and 7 µL A01m-ligated RNA
Heat to 65°C for 2 minutes with lid at 105°C
Place on ice for 1 minute.
Make a master mix. Per reaction add (total 11.5 µL mix):
2.0 µL SSRTIII 10x Buffer
2.0 µL dNTPs (10 mM)
4.0 µL MgCl2 (25 mM)
2.0 µL DTT (100 mM)
0.6 µL RnaseOUT
0.9 µL SSRTIII Enzyme
5. (Old kits fail!)
6. Add 11.5 µL master mix to each 8.5 µL sample (f.v. 20 µL).
7. Vortex briefly and spin down.
8. Heat to 50°C for 45 minutes.
ExoSAP-It degrades primers and dNTPs, and thus only true RNA:cDNA hybrids remain intact.
9. Per reaction add 3.5 µL ExoSAP-It (Thermo 78200.200.UL).
10. Vortex briefly and spin down.
11. Heat to 37°C for 15 minutes.
12. Per reaction add 1 µL EDTA (0.5M). Vortex briefly and spin down.
13. Per reaction add 3 µL 1M NaOH. Vortex briefly and spin down.
14. Heat to 70°C for 12 minutes in thermal cycler to degrade RNA.
15. Per reaction add 3 µL 1M HCl to neutralize pH. (Final volume is 30.5 µL.)

Clean up with MyONE Silane Beads (Abbreviated, see above for full protocol)
Changes to EtOH added and 80% in wash are based on eCLIP protocol but not clear to me why.
1.
2.
3.
4.
5.
6.
7.
8.
9.

Separate 10 µL of MyONE Silane beads per sample.
Wash beads in batch with 900 µL of Qiagen Buffer RLT.
Resuspend beads in 91.5 µL/sample of Qiagen Buffer RLT (3 starting sample volumes).
Add 91.5 µL Beads in Buffer RLT to each sample and mix.
111 µL EtOH (0.91 mix volumes) and mix.
Rotate samples at room temp for 15 minutes.
Separate on magnet for 30 seconds and remove supernatant.
Wash with 0.2 mL 80% EtOH. Resuspend and move to new tube.
Separate on magnet for 30 seconds. Wash 2 more times with 80% EtOH with resuspending (30
seconds on magnet).
10. Dry 5 minutes on magnet.
11. Remove residual EtOH.
12. Resuspend in 9.5~10 µL of H2O and let sit for 5 minutes. Separate on magnet and move 9 µL to a new
set of strip tubes containing 0.5 µL of 80 μM Rand103tr3 adapter.

Rand103tr3 Ligation
NEB has two protocols using T4 RNA Ligase High Concentration. The ligation protocol for a ssRNA oligo to an
RNA molecule has a 2 hour incubation, but the protocol for ligating to DNA says to proceed overnight. T4 RNA
Ligase may be less efficient with ssDNA than it is with RNA but in any case, we have used overnight ligation for
this step and have not tested as to whether that is necessary or whether shorter amount of times are equivalent.
Rand103tr3 Adapter:
/5Phos/NNNNNNNNNNAGATCGGAAGAGCACACGTCTG/3SpC3/
Purify at 100 nmol scale using PAGE Purification, and when asked for random Ns, we used the “Machine
Mixing” option (there are two options, hand mixing and machine mixing). Hand mixing might be better to ensure
equimolar probabilities of random incorporation.
Store in H2O at 200 μM in -20⁰C. Working dilution is 80 μM.
1.
2.
3.
4.

Strip tubes should contain 0.5 µL Rand103tr3 (80 µM) and 9 µL cDNA
Heat to 65°C for 2 minutes with lid at 105°C.
Place on ice for 1 minute
Per reaction add (total 5.5 µL mix):
1.5 µL DMSO (100%)
2.0 µL RNA Ligase Buffer (10x)
2.0 µL ATP (10 mM)
5. Add 5.5 µL mix to each sample.
6. Vortex briefly and spin down.
7. Per reaction add 4 µL PEG8K (50%). (Cut pipette tip for easier pipetting.)
8. Vortex briefly and spin down.
9. Add 1 µL T4 RNA Ligase High Conc (30 U/ µL).
10. Vortex briefly and spin down.
11. Tape down horizontally into a container and place on a shaker at 250 rpm overnight.
Note: Because MyONE Silane allows for purification of small things, some cDNA generated from free A01m
adapter can make it through to this step, thus A01m:Rand103tr3 dimers are possible. The final PCR product of
this adapter is 139 nt. This can be removed by size selection after PCR, and you can run a negative control (no
starting RNA) through the protocol to verify the adapter. If you start with a high concentration of RNA in the
protocol, it seems that very little of this gets made, but if the amount of RNA is limiting, it becomes more
prevalent.
Clean up with MyONE Silane Beads
Unclear to me why the eCLIP protocol switches back to washes in 75% EtOH but we assume that lower
percentage is higher stringency here.

1.
2.
3.
4.
5.
6.
7.
8.

Separate 10 µL of MyONE Silane beads per sample.
Wash beads in batch with 900 µL of Qiagen Buffer RLT.
Resuspend beads in 60 µL/sample of Qiagen Buffer RLT (3 starting sample volumes).
Add 60 µL Beads in Buffer RLT to each sample and mix.
Add 60 µL EtOH (0.75 mix volumes) and mix.
Rotate samples at room temp for 15 minutes.
Separate on magnet for 30 seconds and remove supernatant.
Wash with 0.2 mL 75% EtOH. Resuspend and move to new tube.

9. Separate on magnet for 30 seconds. Wash 2 more times with 75% EtOH with resuspending (30
seconds on magnet).
10. Dry 5 minutes on magnet.
11. Remove residual EtOH.
12. Resuspend in 10 µL of H2O and let sit for 5 minutes.
Trial Library PCR
NEBNext Q5 Ultra II Q5 Master Mix (NEB M0544)
Universal Primer
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC*T
(The * is a phosphorothioate bond, which helps preserve the primer and prevent degradation. Make up at 100
µM and use 10 µM in reaction.)
Index Primers
Can be anything containing the Illumina Read2 priming site with an index that is also compatible with the
adapter ligated template. Here is an SIC index primer (index in lower case)
CAAGCAGAAGACGGCATACGAGATtccgtattaGTGACTGGAGTTCAGACGTGTGCTCTTCCGA
1. Make a master mix. Per sample:
10 µL Q5 Ultra Master Mix
1 µL 10 µM NEBNext Universal primer
7 µL H2O
2. In individual tubes, combine:
1 µL 10 µM Index primer
3. 1 µL adapter ligated cDNA
4. Add 18 µL master mix to index primer/cDNA.
4.0 Run using Q5 Ultra PCR program
98°C
30 sec
(98°C
10 sec
55°C
15 sec
65°C
60 sec) Repeat for N cycles and pull samples at desired cycle numbers and keep on ice.
65°C
5 min
12°C
Hold
Run 2.5% agarose gel/1X TBE. Determine cycle showing robust amplification of library and not high MW
overamplification bands.
We use PCR followed by gel rather than qPCR to determine cycle amplification because it is easier to
appreciate the size of your library as well. We test a few cycles in the range of 10-20. In practice, for 1 μg of input
RNA for total RNA-Seq, we found 10 cycles to be sufficient.

Preparative Library PCR
Cycle number to use should reflect proportional amount of cDNA input. Suppose we 1 µL in a test reaction in
the previous step. If we use 8 µL here, that is 8 fold more starting material, which is 3 base-2 logarithm units. If
15 cycles is determined in the previous step, then use 15-3 = 12 cycles in the preparative PCR.
1. Make a master mix. Per sample:
25 µL Q5 Ultra Master Mix
2.5 µL 10 µM NEBNext Universal primer
12 µL H2O
2. In individual tubes, combine:
2.5 µL 10 µM Index primer
3. 8 µL adapter ligated cDNA
4. Add 39.5 µL master mix to each sample.
5. Run using Q5 Ultra PCR program
98°C
30 sec
(98°C
10 sec
55°C
15 sec
65°C
60 sec ) x desired cycles
65°C
5 min
12°C
Hold
SPRI Purification
Purification is a size selection step using altered polyethylene glycol concentration with Beckman Coulter
AMPure XP beads (Beckman Coulter Product # A63881). This selects for things between 200 - 400 bp (We
have empirically optimized this using a DNA ladder.) You add the beads directly from a well mixed container
without washing them first. It works using the PEG in the bead storage buffer. This is preferable to gel
purification because gel purification results in heavy loss of yield compared to magnetic bead based purification.
It is also preferable to electroelution after gel purification because electroelution does not scale well to large
numbers of samples.
Size selection is important because, especially for small amounts of starting material, the A01m:Rand103tr3
adapter dimer is a prevalent species, and will soak up a lot of reads.
1.
2.
3.
4.
5.
6.
7.

Bring volume to 100 µL with 50 µL H2O.
Add 80 µL of AMPure XP. Mix 10 times by pipetting and incubate 5 minutes.
Separate on magnet.
Move supernatant to new tube.
Add 40 µL of AMPure XP. Mix 10 times by pipetting and incubate 5 minutes.
Separate on magnet 2-3 minutes.
Wash 2x30s 80% EtOH. It is really important with SPRI beads not to disturb them on the magnet. Just
add and let sit for thirty seconds. Remove with multichannel.
8. Dry 5 min.
9. Remove any residual ethanol which collects.
10. Elute in 10 µL of 10 mM Tris pH 7.8.
11. Assay by TapeStation or Bioanalyzer.

Methods S2: Translating Ribosome Affinity Purification (TRAP), Related to Figure 3 and Figure 5.
This protocol based on previous TRAP protocols cited in this manuscript (below) and is intended as an easy
guide to use at the bench. Some modifications have been made to streamline the procedure based on several
years of optimization in the Dougherty Lab.
Dougherty, Joseph D., Susan E. Maloney, David F. Wozniak, Michael A. Rieger, Lisa Sonnenblick,
Giovanni Coppola, Nathaniel G. Mahieu et al. "The disruption of Celf6, a gene identified by translational
profiling of serotonergic neurons, results in autism-related behaviors." Journal of Neuroscience33, no. 7
(2013): 2732-2753.
Heiman, Myriam, Anne Schaefer, Shiaoching Gong, Jayms D. Peterson, Michelle Day, Keri E. Ramsey,
Mayte Suárez-Fariñas et al. "A translational profiling approach for the molecular characterization of CNS
cell types." Cell 135, no. 4 (2008): 738-748.
Doyle, Joseph P., Joseph D. Dougherty, Myriam Heiman, Eric F. Schmidt, Tanya R. Stevens, Guojun
Ma, Sujata Bupp et al. "Application of a translational profiling approach for the comparative analysis of
CNS cell types." Cell 135, no. 4 (2008): 749-762.
Bead Prep
Streptavidin MyONE T1 beads (Thermo 65601) have 2x the binding capacity of Streptavidin M-280 beads
(Thermo 11205D). The quantities below are intended to coat beads with 2-fold molar excess of immunological
components (anti-EGFP antibodies & Pierce biotinylated protein L (Thermo 29997)), based upon the
Dyanbeads User Guide: https://assets.thermofisher.com/TFSAssets/LSG/manuals/MAN0015761_DynabeadsMyOneStreptavidin_T1_UG.pdf
Add 60 μL x N IPs of Streptavidin MyOne T1 or 120 μL x N IPs of Strepatividn M-280 beads to a tube. Put the
tube on the magnet stand and give it a minute to separate. Remove storage buffer (0.1%BSA/1XPBS)
1. Prepare a binding mixture containing:
17 μL of 1 (μg)/(μL) Protein L (17 μg ) x N IPs
20 μL of 1.78* (μg)/(μL) anti-EGFP clone 19F7 (36 μg) x N IPs
36 μL of 1* (μg)/(μL) anti-EGFP clone 19C8 (36 μg) x N IPs
127 μL of 1X PBS (f.v. 200 μL) x N IPs
1.0 actual concentration of antibody will vary lot to lot.
2. Resuspend beads in the antibody/Protein L mixture by pipetting.
3. Incubate beads and antibody/Protein L mixture at room temperature for at least 1 hour with end-overend rotation (or up to overnight at 4C with end-over-end rotation).
4. Put beads on magnet stand and give it a minute to separate.
5. Discard supernatant.
6. Resuspend beads in 1 mL 1XPBS/0.1% BSA. Give it a minute in suspension and a minute on the stand
to wash.
7. Repeat step 7 4 times (total of 5 washes).
8. Resuspend beads in 1 mL of Wash Buffer. Give it a minute in suspension and a minute on the stand to
wash.
9. Repeat step 9 2 times (total of 3 washes).
10. After last wash, resuspend in 1.05xN IPsx100μL Wash Buffer (5% more than the
number of
IPs.)
This step allows you to distribute 100 μL equally to all your IP tubes from the batch of beads. 5% extra
volume ensures that you can do this equally. You will find if you resuspend your beads in 500 μL of lysis

buffer and try to put 100 μL in each of 5 tubes, you will be unable to do so as the detergent in lysis buffer
makes this difficult. You can also plan for N+1 IPs, but this works just as well.
11. Distribute 100 μL to N tubes equal to the number of actual IPs.
12. Keep on ice until you are ready to use them. Remove the Wash buffer you used to aliquot the beads
before use.
Homogenization and Lysis
We use the (1mL) proportions for <half a brain or a near confluent 10cm dish of cells, and the 2 mL proportions
for a whole brain. See referenced papers for recommendations for volume homogenization buffer per mg tissue,
and this may require in-house optimization.
1.
2.
3.
4.

Dissect tissue.
Keep glass mortar(s) on ice and fill each with (1 mL | 2 mL) of lysis buffer.
Move tissue into glass homogenizer.
Take drill fitted with teflon pestle and homogenize up and down 6 times at medium/high power with
power drill.
5. After homogenization, pour off homogenate into a 1.7 mL tube (if homogenizing in 1 mL) or some larger
size of tube that will accommodate your volume (2 mL tubes are nice).
6. Spin 2000 xg, 10 min, 4⁰C.
7. Remove (800 μL | 1.6 mL) of homogenate from Step 6 and move to a new tube and add:
(0.1 mL | 0.2 mL) 10% NP40 (final concentration 1%)
(0.1 mL | 0.2 mL) 300 mM DHPC (final concentration 30 mM)
8. Invert to mix and incubate on ice for 10 minutes.
9. Spin at 20,000xg, 15 minutes, 4C.
10. Measure total lysate. Take 0.1 volumes as Input sample and bring total volume to 250 μL with Wash
Buffer. Add 750 μL Trizol LS and store at -80C until you are ready to extract RNA.
11. Take the remaining 0.9 volumes and resuspend your beads in it.
12. IP for 2 hours.
13. After IP put the samples on the stand and let sit for a minute. Remove the supernatant and discard (you
can also take this supernatant to compare to input if you like, in which case repeat step 10 above).
14. Resuspend in 1 mL of High Salt Wash Buffer. Let sit for a minute in suspension on ice, then a minute on
the stand.
15. Repeat step 14 3 more times (total of 4 washes).
16. Resuspend beads in 250 uL Wash Buffer. Add 750 μL of Trizol LS and store at -80C until you are ready
to extract RNA.
RNA Extraction
1. Bring samples to room temperature if they have been stored at -80C and incubate at room temperature
for 5 minutes. If you haven’t done so already, take out the Glycoblue (stored at -20) and bring to room
temperature.
2. Add 0.2 mL chloroform.
3. Shake vigorously by hand for 15 seconds.
4. Incubate for 7 minutes on bench.
At this point, you can use Phase Lock Gel Heavy tubes to help you separate phases later. Pellet Phase
Lock Gel 12,000 xg, 30 seconds. Add your sample to the pelleted Phase Lock Gel. Mix well but do not
vortex.
5. Centrifuge at 12,000xg, 15minutes, 4C.
6. Vortex the Glycoblue well and spin briefly.

7. Add 2 μL of Glycoblue to new tubes equal to the number of samples you have.
8. Remove the aqueous phase to a new tube (the upper layer) from step (5) to the tubes with glycoblue
and mix well.
9. Add 0.7 volumes of 100% isopropanol.
10. Incubate on the bench for 10 minutes.
11. Centrifuge at 4C, max speed ( ≥ 12,000xg), for 15 minutes.
12. Pour off the supernatant. Do not pipette off the supernatant.
13. Add 1 mL of 80% EtOH. (Dislodge the pellet and invert several times to wash.)
14. Repeat the centrifugation in step 11.
15. Pour off the supernatant. Be careful not to dislodge pellet.
16. Leave tubes open on your tube rack while you prepare the DNase treatment mix (3-5 minutes. Do not
overdry!). (This paper and protocol uses NEB Rnase-free DNase I (M0303) but we have also used this
protocol with Qiagen DNase and this works well. Likely most DNase kits will be appropriate).
DNase Treatment Mix:
2 μL 10X NEB DNase I buffer x n+1 samples
87 μL H2O x n+1 samples
3 μL Qiagen DNase I x n+1 samples
17. Resuspend the pellet in 20 μL of DNase Treatment Mix.
18. Incubate at 37 C for 15 minutes.
19. Clean up RNA with Zymo RNA Clean & Concentrator 5 (> 17 nt), Qiagen RNeasy kit (>200 nt), or
MyONE Silane Dynabeads (see Methods S1)*.
Reagent Recipes
0.1% BSA/1XPBS
Add IgG-Free Bovine Serum Albumen (100 mg per 10 mL) to 1X PBS and allow to rock gently for >10
minutes to go into solution (1% BSA). Dilute 1% BSA/1XPBS 10-fold.
10% NP40
Carefully make up 10% v/v NP40 (IGEPAL CA-630, Sigma) by pipetting 100% NP4O into H2O and let
rock for >10 minutes to fully dilute.
300 mM DHPC
Resuspend 100 mg 07:0 PC (DHPC, Avanti polar lipids) in 692 μL of H2O. To avoid foaminess, add
H2O and let it rock for a few minutes and then transfer to Eppendorf tubes.
100 mg/mL cycloheximide
Dissolve cycloheximide in 100% methanol at 100 mg/mL.
7X Roche cOmplete EDTA-free protease inhibitor
Crush tablet in a small volume (~300-500 μL) of water. Pipette up and down to start to dissolve. Bring
volume to 1.5 mL and mix until fully dissolved.
Add DTT, RNasin, Superase-In, protease inhibitor, and cycloheximide just prior to use.
Homogenization Buffer

10 mM HEPES pH 7.4
150 mM KCl
5 mM MgCl2
0.5 mM dithiothreitol
1 μL/mL rRNasin
1 μL/mL SUPERase-in
1 X cOmplete EDTA-free protease inhibitor
100 μg/mL cycloheximide
Wash Buffer
10 mM HEPES pH 7.4
150 mM KCl
5 mM MgCl2
1 % NP-40
0.5 mM dithiothreitol
1 μL/mL rRNasin
1 μL/mL SUPERase-in
1 X cOmplete EDTA-free protease inhibitor
100 μg/mL cycloheximide
High Salt Wash Buffer
10 mM HEPES pH 7.4
350 mM KCl
5 mM MgCl2
1 % NP-40
0.5 mM dithiothreitol
1 μL/mL rRNasin
1 μL/mL SUPERase-in
1 X cOmplete EDTA-free protease inhibitor
100 μg/mL cycloheximide

Methods S3: Preparing PTRE-Seq samples for Next Generation Sequencing, Related to Figure 3 and
Figure 5.
The input into this procedure for generating sequencing libraries from PTRE-Seq samples is either extracted
and purified library RNA or library plasmid DNA. To prepare for sequencing from plasmid DNA, skip cDNA
synthesis and proceed to “ds cDNA amplification and plasmid DNA amplification”. If processing samples in
parallel, the samples can be synchronized from the amplification step forward as indicated. Procedure is based
on mRNA synthesized off of the pmrPTRE_AAV backbone (see Key Resource Table). Plasmid map available
upon request.
For multiplexing, this protocol assumes use of a Permagen Labware strip tube magnet separator ( see Methods
S1).
cDNA Synthesis
pmrPTRE Antisense oligo: GGCACTGGAGTGGCAACT
Superscript III Reverse Transcriptase: Thermo 18080093
(Note the only apparent differences between buying the enzyme alone or in the First Strand Synthesis kit is that
the MgCl2 is included in the 5X First Strand Buffer in product 18080093, and the enzyme kit alone does not
include dNTPs).
1. Add 2.5 μL of 12 μM pmrPTRE Antisense oligo to each tube.
2. Add 8.0 μL of RNA/water to each tube containing 10 ng of RNA. (This protocol, cycle numbers etc. in
downstream steps, was developed with starting 10 ng of RNA, however could be scaled up or potentially
even down, though some cycle numbers may have to be optimized to avoid over-amplification. No rRNA
depletion is performed as the library is amplified using oligonucleotide primers specific to the
pmrPTRE_AAV plasmid.)
3. Heat to 65○C for 2 minutes with lid at 105○C. Place immediately on ice for 1 minute.
4. Make mastermix, per reaction:
4 uL 5X First Strand Buffer
2 uL 10 mM dNTPs
2 uL 100 mM dithiothreitol
0.6 uL Promega rRNasin (N2515)
0.9 uL SSRT III RT enzyme
5. Add 9.5 μL of mastermix to each sample.
6. Incubate all at 50⁰C for 45 minutes.
7. Add 3.5 μL of ExoSAP-It (Thermo 78200.200.UL).
8. Vortex & spin
9. Heat to 37⁰C for 15 minutes. (f.v. 23.5)
10. Add 1 μL 0.5 M EDTA per reaction. Vortex & spin. (f.v. 24.5)
11. Add 3 μL 1 M NaOH. Vortex and Spin. (f.v. 27.5)
12. Heat to 70C for 12 minutes.
13. Add 3 μL 1M HCl. Vortex and Spin. (f.v. 30.5)
14. Clean up with MyONE Silane Dynabeads (see Methods S1 for full procedural description). Briefly:
a. Wash beads with 900 μL RLT
b. Resuspend in 91.5 μL/sample buffer RLT
c. Add 91.5 μL to each sample and mix (f.v. 122)
d. Add 111 μL 100% EtOH. Incubate 15 minutes. (f.v. 233)
e. Wash MyONE silane style 3x0.2mL 80% EtOH. First wash, fully resuspend. Washes 2&3 just
wash on magnet.

f. Dry 5 minutes.
g. Remove any excess EtOH.
h. Elute in 12 μL 50 mM Tris pH 7.8 and incubate 5 minutes before clarifying.

ds cDNA amplification and plasmid DNA amplification
NEB Phusion High-Fidelity Polymerase (NEB M0530)
PTRE sense oligo: GCATGGACGAGCTGTACAAG
PTRE antisense oligo: as in cDNA synthesis
If using Plasmid DNA, dilute to approximately 5 ng/μL.
1. Seed 20 μL PCR reaction with 8 μL of eluted cDNA sample from the previous step, or 8 μL of 5 ng/μL
DNA samples. Per reaction:
10.0 μL 2X Phusion HF Master Mix (NEB M0530)
1.0 μL 10 μM PTRE UTR antisense 1 (x25= 25)
1.0 μL 10 μM PTRE UTR sense 1 (x25 = 25)
8.0 μL cDNA
2. Add 12 μL of master mix to each 8 μL sample.
3. Run following program:
98oC 30s
98oC 10s, 60oC 10s, 72oC 15s | 12 cycles (plasmid DNA) or 18 cycles (cDNA)
72oC 10 min
4oC ∞
Product size: 245 bp
Product sketch:

Note the location of the KpnI & NheI sites. This procedure adapts the Illumina P1 priming site to the KpnI
restriction site, such that the 9 bp element barcode will be read as the beginning of Read 1 of sequencing.

AMPure 80/40 selection
Purification/size selection steps use Beckman Coulter AMPure XP beads (Beckman Coulter A63881) to size
select to a range ~200-400 bp thus purifying the product from the previous step with high yield. We recommend
this against gel extraction for simplicity and yield, however 2% agarose gels were used in development to verify
correct size of amplicon (See Methods S1).
1.
2.
3.
4.
5.
6.
7.

Bring AMPure XP beads to room temperature ~30 min.
Bring volume to 100 μL with H2O (add 80 μL).
Vortex beads and pipette 80 μL and add to PCR products. Mix by pipetting up and down 10x.
Incubate on bench 5 minutes.
Put on strip tube magnet for 3 minutes.
Re-vortex beads and pipette 40 μL to a clean strip tube.
Harvest supernatant (~160 μL recoverable) and add to new tube with 40 μL beads in it. Mix by pipetting
up and down 10x.
8. Incubate on bench 5 minutes.
9. Put on strip tube magnet 3 minutes.
10. Wash beads on magnet with 200 μL 80% EtOH for 30 seconds. Do not disturb pellet. Add wash, let sit,
then remove.
11. Repeat for total of two washes.
12. Dry beads for 5 minutes and remove any excess EtOH with vacuum or by pipette.
13. Resuspend beads in 10.5 μL Buffer EB (so that it will be possible to recover 10 μL) and incubate on
bench 5 minutes.
14. Add to magnet for 1 minute and harvest 10 μL.
NheI/KpnI Digest
This procedure digests the double stranded products generated above to prepare for adapter ligation. Uses
NEB enzymes NheI-HF (R3131) and KpnI-HF (R3142).
1. Remove 10 μL of purified PCR product and add to:
2 μL 10X CutSmart Buffer
1 μL NheI HF
1 μL KpnI HF
6 μL H2O
2. Mix well, spin, and incubate in thermal cycler for 1 hour at 37oC with lid set to 40oC.
3. During protocol optimization, we verified digest by running products out on an Agilent TapeStation
instrument. Digested product 160 bp.
4. AMPure 100/50 selection
5. This selection has altered volumes of AMPure XP to select against undigested PCR product. Purity of
products was confirmed by Agilent TapeStation.
6. Bring volume to 100 μL with H2O (80 μL).
7. Vortex beads and pipette 100 μL and add to digested products. Mix by pipetting up and down 10x.
8. Incubate on bench 5 minutes.
9. Put on strip tube magnet for 3 minutes.
10. Re-vortex beads and pipette 50 μL to a clean strip tube.
11. Harvest supernatant and add to new tube with 50 μL beads in it. Mix by pipetting up and down 10x.
12. Incubate on bench 5 minutes.
13. Put on strip tube magnet 3 minutes.

14. For QC, save the first bead pellet. This is the first round of selection. Mostly selects out high MW species,
but may select out a bit of desired product too.
15. Wash beads on magnet with 200 μL 80% EtOH for 30 seconds. Do not disturb pellet. Add wash, let sit,
then remove.
16. Repeat for total of two washes.
17. Dry beads for 5 minutes and remove any excess EtOH with vacuum or by pipette.
18. Resuspend beads in 10.5 μL Buffer EB (so that it will be possible to recover 10 μL) and incubate on
bench 5 minutes.
19. Add to magnet for 1 minute and harvest 10 μL.
Staggered Adapter Preparation
In order to generate sufficient sequence diversity for next generation sequencing, the KpnI/P1 adapter
containing a priming site for the Illumina P1, is ligated as a mix of 4 adapters which are staggered in length (see
Table S9 and below ):
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCATGTA*C

KpnI_overhang_1

ACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGGTGTA*
C

KpnI_overhang_2

ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTTCCTGTA*
C

KpnI_overhang_3

ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGCAGCTGT
A*C

KpnI_overhang_4

/5phos/A*TGAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTG KpnI_complement_1
T-3
/5phos/A*CCTGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGT KpnI_complement_2
GT-3
/5phos/A*GGAACAGATCGGAAGAGCGTCGTGTAGGGAAAGA
GTGT-3

KpnI_complement_3

/5phos/A*GCTGCTAGATCGGAAGAGCGTCGTGTAGGGAAAGA KpnI_complement_4
GTGT-3
/5phos/C*TAGAGATCGGAAGAGCACACGTCTG

NheI_overhang

CAGACGTGTGCTCTTCCGATC*T

NheI_complement

1. Prepare synthesized KpnI adapters and NheI/P2 adapters as 100 uM in 1X TE or Tris pH 8 buffer.
2. Make 1:1 equimolar mixes (f.c. 10 uM each adapter) of “overhang” and “complement” (final volume is
arbitrary).
3. Heat adapter mixes to 95C for 3 minutes.
4. Move to bench and let cool to room temperature to anneal double stranded adapters.
5. Move to ice.
6. Make a 1:1:1:1 equimolar mix of KpnI double stranded adapters (final concentration 1 uM each adapter).
7. Make a 1 uM dilution of NheI adapter.

Adapters are now ready for ligation. Barcode sequences will be the first nucleotides read in Read 1 of illumina
sequencing.
Adapter Ligation
T4 DNA Ligase (L6030-LC)
1. Combine 10 μL purified/digested PCR product in the follow reaction
6 μL H2O
2 μL Enzymatics T4 DNA Ligase buffer 10X
0.5 μL 1 μM NheI/P2 adapter
0.5 μL 1 μM mix of KpnI/P1 adapters 1-4
1 μL of Enzymatics T4 DNA Ligase
2. Incubate at 16 C for 1 hour
3. Purify products with Ampure 80/40 procedure (above) and elute in 10.5 μL EB, and harvest 10 μL.

After adapter ligation, products will be ~220 bp. Ligation can be confirmed by Agilent TapeStation.
Preparative PCR for Sequencing
As in Methods S1, this procedure is performed using NEB Q5 Ultra II PCR master mix (M0544). Trial PCR was
run followed by agarose gel electrophoresis to optimize cycle number.
Illumina Univ. F: AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC*T
Index Reverse Primer:
CAAGCAGAAGACGGCATACGAGATxxxxxxxxxGTGACTGGAGTTCAGACGTGTGCTCTTCCG*A
“xxxxxxxxx” represents a 9bp unique sample index for demultiplexing.
1. Master mix:
25 μL NEB Q5 Ultra II pcr master mix
2.5 μL 10 μM universal primer
12 μL H2O
2. Aliquot 39.5 to each adapter-ligated DNA sample.
3. Add 2.5 μL of index primer.
4. Run with Q5 program for 9 cycles:
98oC 30 s
(98oC 10 s | 55oC 15 s | 65oC 1 min) X 9
65oC 5 min
12oC hold
5. Purify with 80/40 AMPure XP procedure as above.
6. Assay purity and molar concentration of NGS library PCR products by Agilent TapeStation.

